haloperidol has been researched along with Disease Models, Animal in 516 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate Haloperidol's (Hal) effects on the behavioral, neurotrophic factors, and epigenetic parameters in an animal model of schizophrenia (SCZ) induced by ketamine (Ket)." | 8.31 | Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. ( da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI, 2023) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 8.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD)." | 8.02 | Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ( Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC, 2021) |
| "Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnormalities." | 7.96 | Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. ( Babinska, Z; Bucolo, C; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Fedotova, J; Giurdanella, G; Iannotti, FA; Kratka, L; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Platania, CBM; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2020) |
| "Risperidone, 5-HT2A receptor antagonists, and D1 receptor antagonistic drugs prevented and reversed cocaine-induced hyperthermia." | 7.96 | Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. ( Makiguchi, A; Okada, T; Shioda, K; Suda, S, 2020) |
| "Asenapine maleate (AM) is an atypical antipsychotic that, unlike many other antipsychotics, shows some efficacy in treating cognitive dysfunction in schizophrenia." | 7.91 | Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. ( Foute Nelong, T; Manduca, JD; Perreault, ML; Zonneveld, PM, 2019) |
| "Clinical studies that focused on treating schizophrenia showed that Calculus Bovis Sativus (CBS), a substitute of Calculus Bovis, when used in combination with haloperidol could significantly lower the dosage of haloperidol compared with treatment with haloperidol alone, whereas efficacy was maintained." | 7.88 | Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. ( He, GF; He, GZ; Lei, K; Li, J; Li, XP; Liu, D; Liu, YN; Ren, XH; Zhang, CL, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 7.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| "Tardive dyskinesia (TD) is associated with the use of antipsychotic drugs such as D2 antagonist haloperidol (HP)." | 7.85 | Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats. ( Haleem, DJ; Samad, N, 2017) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 7.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD)." | 7.83 | Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. ( Haleem, DJ; Samad, N; Yasmin, F, 2016) |
| "We thus propose the l-methionine treatment as an animal model recapitulating several symptoms of schizophrenia." | 7.81 | A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity. ( Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z, 2015) |
| "This study used electromyography to describe tremulous jaw movement generated by bilateral electrolytic lesion in the VLS and compare it to tremors induced using subchronic IP treatment with haloperidol, a dopaminergic D2 receptor antagonist." | 7.80 | Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison. ( García, LI; Hernández, ME; Herrera-Meza, G; Manzo, J; Miquel, M, 2014) |
| "Aripiprazole (APZ) is considered a first-line medication for treating first and multiple episodes of schizophrenia, but its effect on preventing the progressive pathophysiology of schizophrenia remains unclear." | 7.77 | Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. ( Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y, 2011) |
| "This study compared effects of the mu opioid receptor agonist morphine (an acknowledged analgesic), the dopamine receptor antagonist haloperidol (a non-analgesic sedative), the adenosine receptor antagonist caffeine (a non-analgesic stimulant) and the neurokinin-1 receptor antagonist CJ 11,974-01 (a candidate analgesic) on acetic acid-induced writhing (a traditional pain-stimulated behavior) and acetic acid-induced suppression of locomotor activity (a pain-depressed behavior) in male ICR mice." | 7.75 | Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. ( Adams, C; Bilsky, EJ; Cormier, J; Dunbar, C; Mercer, H; Negus, SS; Stevenson, GW, 2009) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 7.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 7.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| " We used SH-SY5Y cells, differentiated into neuron-like type, to evaluate if cabergoline, a dopamine D2 receptor agonist endowed with anti-oxidant activity, protects the cells against ischemia (oxygen-glucose deprivation model)." | 7.72 | Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia. ( Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F, 2004) |
| "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe." | 7.72 | Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol. ( Laszczyńska, M; Piasecka, M; Słuczanowska-Glabowska, S; Wylot, M, 2004) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 7.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "The modulation of cerebellar Purkinje cell activity and EEG from parietal cortex was studied in the rat model of epilepsy induced by penicillin under acute haloperidol and amphetamine treatment." | 7.69 | Amphetamine and haloperidol modulatory effects on Purkinje cell activity and on EEG power spectra in the acute rat model of epilepsy. ( Culić, M; Janković, B; Rakić, L; Saponjić, J, 1994) |
| " Experimental rabbits treated with haloperidol (1 mg/kg) by intramuscular injection, were studied for the diagnostic symptoms of increased muscle rigidity, elevated body temperature, and high serum creatine phosphokinase (CPK) level." | 7.69 | Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. ( Hosono, T; Ikura, Y; Kudo, T; Niigawa, H; Nishimura, T; Sakamoto, S; Takeda, M; Taniguchi, N; Tanii, H, 1996) |
| " Oscillations in forelimb force during this performance were spectrally analyzed to describe the tremorogenic effects of haloperidol (0." | 7.68 | A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat. ( Fowler, SC; Liao, RM; Skjoldager, P, 1990) |
| "Catalepsy was induced by systemic haloperidol (0." | 5.56 | Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats. ( Ihme, H; Melo-Thomas, L; Schwarting, RKW, 2020) |
| "Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia." | 5.51 | Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. ( Cavalcanti, DMLP; Cavalcanti, JRLP; da Silva, ANA; da Silva, MSM; de Araújo, DP; de Sales, LGP; Guzen, FP; Pinheiro, FI, 2019) |
| "Anhedonia is a relevant symptom in depression and schizophrenia." | 5.42 | Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats. ( De Montis, MG; Ferrari, A; Gambarana, C; Pelliccia, T; Scheggi, S, 2015) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 5.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | 5.40 | Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. ( Fang, Y; Xu, L; Zhang, C, 2014) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 5.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 5.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| "Treatment with haloperidol and clozapine attenuated the detrimental performance effects of these challenges, with clozapine exhibiting more robust attenuation." | 5.35 | Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. ( Martinez, V; Sarter, M, 2008) |
| "The treatment with haloperidol worsened the adverse effects of chronic social stress having effects similar to stress on reward and motivation-related behaviours." | 5.35 | Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. ( Abumaria, N; Flügge, G; Fuchs, E; Havemann-Reinecke, U; Hiemke, C; Rüther, E; Rygula, R; Zernig, G, 2008) |
| " A pilot dose-response study investigated an intracranial approach of topically applying endothelin-1 (ET-1) to the M2 portion of the middle cerebral artery in a small sample of marmosets for up to 6 hours (n = 2 or 3 per group)." | 5.32 | A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset. ( David, C; Elliott, H; Farnfield, B; Golder, J; Hadingham, SJ; Hunter, AJ; Parsons, AA; Roberts, JC; Virley, D; Whelan, G, 2004) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 5.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "Haloperidol and clozapine were tested in rats after daily administration for 3 and 21 days in combination with vehicle or PCP (2." | 5.30 | A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. ( Sams-Dodd, F, 1998) |
| "Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia." | 5.07 | Clozapine in tardive dyskinesia: observations from human and animal model studies. ( Gao, XM; Kakigi, T; Moran, M; Tamminga, CA; Thaker, GK, 1994) |
| " Second, we review the studies that have examined latent inhibition in populations with schizophrenia and in healthy populations after administration of amphetamine or haloperidol." | 4.88 | The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)? ( Le Pelley, M; Schmidt-Hansen, M, 2012) |
| "This study aimed to evaluate Haloperidol's (Hal) effects on the behavioral, neurotrophic factors, and epigenetic parameters in an animal model of schizophrenia (SCZ) induced by ketamine (Ket)." | 4.31 | Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine. ( da Rosa, RT; Dal-Pont, GC; Daminelli, T; Fries, GR; Mastella, GA; Quevedo, J; Valvassori, SS; Varela, RB; Zugno, AI, 2023) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 4.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD)." | 4.02 | Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ( Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC, 2021) |
| "Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnormalities." | 3.96 | Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. ( Babinska, Z; Bucolo, C; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Fedotova, J; Giurdanella, G; Iannotti, FA; Kratka, L; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Platania, CBM; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2020) |
| "Risperidone, 5-HT2A receptor antagonists, and D1 receptor antagonistic drugs prevented and reversed cocaine-induced hyperthermia." | 3.96 | Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats. ( Makiguchi, A; Okada, T; Shioda, K; Suda, S, 2020) |
| "Antipsychotic drugs haloperidol and clozapine have been reported to increase the sensitivity of retinal ganglion cells (RGCs) to flashes of light in the P23H rat model of retinitis pigmentosa." | 3.91 | Differential effects of antipsychotic drugs on contrast response functions of retinal ganglion cells in wild-type Sprague-Dawley rats and P23H retinitis pigmentosa rats. ( Jensen, R, 2019) |
| "Asenapine maleate (AM) is an atypical antipsychotic that, unlike many other antipsychotics, shows some efficacy in treating cognitive dysfunction in schizophrenia." | 3.91 | Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia. ( Foute Nelong, T; Manduca, JD; Perreault, ML; Zonneveld, PM, 2019) |
| "The methionine-folate cycle-dependent one-carbon metabolism is implicated in the pathophysiology of schizophrenia." | 3.88 | Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits. ( Abbott, GW; Alachkar, A; Civelli, O; Hamzeh, AR; Lee, SM; Sanathara, N; Wang, L; Wang, Z; Xu, X; Yoshimura, R, 2018) |
| "Clinical studies that focused on treating schizophrenia showed that Calculus Bovis Sativus (CBS), a substitute of Calculus Bovis, when used in combination with haloperidol could significantly lower the dosage of haloperidol compared with treatment with haloperidol alone, whereas efficacy was maintained." | 3.88 | Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. ( He, GF; He, GZ; Lei, K; Li, J; Li, XP; Liu, D; Liu, YN; Ren, XH; Zhang, CL, 2018) |
| " effect of test drug on clonidine and haloperidol induced catalepsy, milk-induced leukocytosis and eosinophilia, mast cell stabilizing activity in mice and studies on smooth muscle preparation of guinea pig ileum (in-vitro)." | 3.88 | Antiallergic and antihistaminic actions of Ceasalpinia bonducella seeds: Possible role in treatment of asthma. ( Nirmal, S; Vikhe, S, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 3.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| "Tardive dyskinesia (TD) is associated with the use of antipsychotic drugs such as D2 antagonist haloperidol (HP)." | 3.85 | Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats. ( Haleem, DJ; Samad, N, 2017) |
| "Rodents exposed prenatally to valproic acid (VPA) exhibit autism spectrum disorder (ASD)-like behavioral abnormalities." | 3.85 | Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Kawase, H; Matsuda, T; Nakazawa, T; Takuma, K; Tanabe, W; Taruta, A; Tsukada, S, 2017) |
| "We performed quantitative PCR and western blot analysis to measure PSD-95 expression in schizophrenia vs control subjects, rodent haloperidol treatment studies, rodent postmortem interval studies, and GluN1 knockdown (KD) mice vs controls." | 3.85 | Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia. ( Funk, AJ; Koene, R; Lipska, BK; McCullumsmith, RE; Mielnik, CA; Newburn, E; Ramsey, AJ, 2017) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 3.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD)." | 3.83 | Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. ( Haleem, DJ; Samad, N; Yasmin, F, 2016) |
| " phencyclidine (PCP), produces prolonged impairment of novel object recognition (NOR), suggesting they constitute a hypoglutamate-based model of cognitive impairment in schizophrenia (CIS)." | 3.81 | Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. ( Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L, 2015) |
| " Here we evaluated the potential of the typical antipsychotic drug haloperidol to modulate the cholesterol efflux function of macrophages in vitro and their susceptibility to atherosclerosis in vivo." | 3.81 | Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice. ( Hoekstra, M; Nahon, JE; Reuwer, AQ; van der Sluis, RJ; Van Eck, M, 2015) |
| "Dopaminergic signaling has long been known to be a critical factor in nicotine addiction, as well as other drugs of abuse." | 3.81 | Neuro-anatomic mapping of dopamine D1 receptor involvement in nicotine self-administration in rats. ( Allenby, C; Hall, BJ; Kutlu, MG; Levin, ED; Slade, S, 2015) |
| "We thus propose the l-methionine treatment as an animal model recapitulating several symptoms of schizophrenia." | 3.81 | A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity. ( Alachkar, A; Belluzzi, JD; Civelli, O; Sanathara, N; Wang, L; Wang, Z, 2015) |
| "This study used electromyography to describe tremulous jaw movement generated by bilateral electrolytic lesion in the VLS and compare it to tremors induced using subchronic IP treatment with haloperidol, a dopaminergic D2 receptor antagonist." | 3.80 | Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison. ( García, LI; Hernández, ME; Herrera-Meza, G; Manzo, J; Miquel, M, 2014) |
| " TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation." | 3.79 | A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. ( Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG, 2013) |
| "We compared the effects of subchronic clozapine and haloperidol administration on the expression of SNAP-25 and synaptophysin in an animal model of schizophrenia based on the glutamatergic hypothesis." | 3.78 | Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice. ( Basar, K; Ertugrul, A; Ozdemir, H; Saka, E, 2012) |
| "The effect of course treatment with neuroleptic haloperidol on the inflammatory response and state of the connective tissue in the lungs of C57Bl/6 mice was studied on the model of toxic pulmonary fibrosis induced by intratracheal administration of bleomycin." | 3.78 | Antifibrotic and anti-inflammatory activity of a neuroleptic drug on the model of pulmonary fibrosis. ( Andreeva, TV; Dygai, AM; Ermolaeva, LA; Khmelevskaya, ES; Krupin, VA; Pershina, OV; Reztsova, AM; Skurikhin, EG; Stepanova, IE, 2012) |
| "Aripiprazole (APZ) is considered a first-line medication for treating first and multiple episodes of schizophrenia, but its effect on preventing the progressive pathophysiology of schizophrenia remains unclear." | 3.77 | Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. ( Abekawa, T; Ito, K; Koyama, T; Nakagawa, S; Nakato, Y, 2011) |
| " To complete our understanding, here we studied neurogenesis and its sensitivity to the classical neuroleptic haloperidol in a developmental model of schizophrenia (maternal vitamin D deficiency)." | 3.76 | Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats. ( Becker, A; Grecksch, G; Keilhoff, G, 2010) |
| "Haloperidol is a potent dopamine receptor antagonist and used to treat psychotic disorders, such as schizophrenia." | 3.76 | Neonatal ventral hippocampus lesion induces increase in nitric oxide [NO] levels which is attenuated by subchronic haloperidol treatment. ( Aguilar-Alonso, P; Baltazar-Gaytán, E; Bringas, ME; Flores, G; León-Chávez, BA; Negrete-Díaz, JV; Newton, S; Vazquez-Roque, RA, 2010) |
| "Ketamine-induced alterations in EEG power spectra are consistent with abnormalities in the theta and gamma frequency ranges reported in patients with schizophrenia." | 3.75 | N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. ( Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI, 2009) |
| "We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mechanical hypersensitivity (allodynia) and on nociceptive pain induced by punctate mechanical stimuli in mice." | 3.75 | Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. ( Baeyens, JM; Cendán, CM; Cobos, EJ; Del Pozo, E; Entrena, JM; Nieto, FR, 2009) |
| "This study compared effects of the mu opioid receptor agonist morphine (an acknowledged analgesic), the dopamine receptor antagonist haloperidol (a non-analgesic sedative), the adenosine receptor antagonist caffeine (a non-analgesic stimulant) and the neurokinin-1 receptor antagonist CJ 11,974-01 (a candidate analgesic) on acetic acid-induced writhing (a traditional pain-stimulated behavior) and acetic acid-induced suppression of locomotor activity (a pain-depressed behavior) in male ICR mice." | 3.75 | Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. ( Adams, C; Bilsky, EJ; Cormier, J; Dunbar, C; Mercer, H; Negus, SS; Stevenson, GW, 2009) |
| " Given that atypical antipsychotics have been shown to ameliorate negative symptoms of schizophrenia more effectively than typical neuroleptics, this effect should be reversed by clozapine but not haloperidol." | 3.74 | Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats. ( Hulick, VC; Turgeon, SM, 2007) |
| "Disruptions in 5-CSRTT performance induced by repeated PCP administration are prevented by chronic clozapine treatment and may constitute a useful animal model of some cognitive symptoms of schizophrenia." | 3.74 | Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. ( Amitai, N; Markou, A; Semenova, S, 2007) |
| " We previously reported that baclofen, the prototypical GABA(B) agonist, elicits antipsychotic-like effects in the rat paradigm of prepulse inhibition (PPI) of the startle, a highly validated animal model of schizophrenia." | 3.74 | Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. ( Bortolato, M; Castelli, MP; Fà, M; Frau, R; Gessa, GL; Marrosu, F; Mereu, G; Orrù, M; Piras, AP; Puligheddu, M; Tuveri, A, 2007) |
| "To develop a mouse model to mimic the behavioral and neurochemical changes of Tourette syndrome (TS) by 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induction and to investigate the effects of fluoxetine and haloperidol on head twitch response (HTR) induced by DOI." | 3.74 | [Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response]. ( Dai, XM; Lu, Y; Ma, HW; Yao, Y, 2007) |
| "Sub-chronic phencyclidine (PCP) treatment mimics certain aspects of schizophrenia symptomology in rats." | 3.74 | Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. ( Neill, JC; Snigdha, S, 2008) |
| "Bupropion reduced the amplitude and gating of the N40 evoked potential in mice, similar to the P50 and N100 endophenotypes associated with sensory encoding deficits in schizophrenia." | 3.73 | Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. ( Gur, RE; Kanes, SJ; Lerman, C; Liang, Y; Majumdar, S; Maxwell, CR; Siegel, SJ; Trief, DF, 2005) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 3.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "5 and 2 mg of olanzapine, but not lower doses, increase body weight and subcutaneous fat deposition." | 3.73 | A model for antipsychotic-induced obesity in the male rat. ( de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D, 2006) |
| "Several clinical reports have demonstrated that most antipsychotics of the new generation, but not the typical antipsychotic haloperidol, induce weight gain in schizophrenic patients." | 3.72 | Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. ( Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S, 2003) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 3.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| " Previous research has reported that haloperidol induces tremulous jaw movements that have many of the characteristics of parkinsonian tremor." | 3.72 | The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. ( Betz, A; Correa, M; Dobson, DR; O'Neill, MF; O'Neill, MJ; Salamone, JD; Wisniecki, A, 2004) |
| " We used SH-SY5Y cells, differentiated into neuron-like type, to evaluate if cabergoline, a dopamine D2 receptor agonist endowed with anti-oxidant activity, protects the cells against ischemia (oxygen-glucose deprivation model)." | 3.72 | Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia. ( Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F, 2004) |
| "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe." | 3.72 | Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol. ( Laszczyńska, M; Piasecka, M; Słuczanowska-Glabowska, S; Wylot, M, 2004) |
| " Muscle rigidity was assessed quantitatively and objectively as increases in electromyographic (EMG) activity (muscle rigidity) in the hindlimb muscles of the rat following subcutaneous administration of haloperidol, fluphenazine and thioridazine." | 3.71 | An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. ( Crocker, AD; Hemsley, KM, 2001) |
| "The aim of the present study was to determine whether S-4-carboxy-3-hydroxyphenylglycine (S)-4C3HPG, a mixed group I glutamate metabotropic receptor antagonist and a group II agonist, attenuated parkinsonian-like muscle rigidity in rats." | 3.71 | (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S, 2001) |
| " In the present study, JL13 was compared with clozapine and haloperidol in several animal models for schizophrenia." | 3.71 | Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. ( Bruhwyler, J; Cools, AR; Ellenbroek, BA; Liégeois, JF, 2001) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 3.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA." | 3.71 | An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001) |
| "The enhancement of immobility in a forced swimming test of mice induced by repeated treatment with phencyclidine and amphetamine swimming "normalization" test of mice were used as animal models of negative and positive symptoms of schizophrenia, respectively." | 3.70 | Atypical antipsychotic effects of quetiapine fumarate in animal models. ( Dai, J; Guan, HJ; Zhu, XZ, 2000) |
| "Although diphenhydramine hydrochloride is known to eliminate or reduce the symptoms of dystonia in human patients with acute dystonic reactions and idiopathic torsion dystonia, its mechanism of action is still unclear." | 3.69 | Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine. ( Matsumoto, RR; Stone, MR; Truong, DD; van't Groenewout, JL; Vo, VN, 1995) |
| "The modulation of cerebellar Purkinje cell activity and EEG from parietal cortex was studied in the rat model of epilepsy induced by penicillin under acute haloperidol and amphetamine treatment." | 3.69 | Amphetamine and haloperidol modulatory effects on Purkinje cell activity and on EEG power spectra in the acute rat model of epilepsy. ( Culić, M; Janković, B; Rakić, L; Saponjić, J, 1994) |
| "Activated lipid peroxidation observed in brain homogenates in experimental choreoid hyperkinesis and bemegride epilepsy can be arrested by antioxidant pretreatment." | 3.69 | [The role of lipid peroxidation in the pathogenesis of neuropathological syndromes and in experimental therapy]. ( Aliev, AN; Aliev, MN; Mamedbeĭli, TN; Rzaev, RN, 1994) |
| " Experimental rabbits treated with haloperidol (1 mg/kg) by intramuscular injection, were studied for the diagnostic symptoms of increased muscle rigidity, elevated body temperature, and high serum creatine phosphokinase (CPK) level." | 3.69 | Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. ( Hosono, T; Ikura, Y; Kudo, T; Niigawa, H; Nishimura, T; Sakamoto, S; Takeda, M; Taniguchi, N; Tanii, H, 1996) |
| " The aim of this work was to investigate whether the D-1 antagonist SCH 23390 differs from haloperidol (D-2 antagonist) in models of experimental epilepsy induced by electrical stimulation of selected brain regions (hippocampus and amygdala), in rabbits." | 3.68 | [Role of the dopaminergic system in experimental models of epilepsy]. ( Albergati, A; Bo, P; Murelli, R; Savoldi, F; Soragna, D, 1993) |
| "The effects of the atypical neuroleptic clozapine were studied in an inbred line of Syrian golden hamsters with generalized dystonia, i." | 3.68 | The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol. ( Löscher, W; Richter, A, 1993) |
| " Oscillations in forelimb force during this performance were spectrally analyzed to describe the tremorogenic effects of haloperidol (0." | 3.68 | A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat. ( Fowler, SC; Liao, RM; Skjoldager, P, 1990) |
| "Several useful animal models for parkinsonism have been developed so far." | 2.72 | Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. ( Alves, CO; de Oliveira, AR; Magalhães, MS; Waku, I, 2021) |
| " We exemplify how this dosing confounder could lead to inappropriate conclusions." | 2.41 | Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. ( Kapur, S; Remington, G; Wadenberg, ML, 2000) |
| "Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man." | 2.37 | Acute dystonia induced by neuroleptic drugs. ( Jenner, P; Marsden, CD; Rupniak, NM, 1986) |
| "Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality." | 1.62 | Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. ( Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J, 2021) |
| "Haloperidol is an antipsychotic agent recently described as an antinociceptive drug able to mediate the antagonism of sigma-1 receptors while morphine is an opioid used in the treatment of neuropathic pain." | 1.62 | Haloperidol potentiates antinociceptive effects of morphine and disrupt opioid tolerance. ( Blanco-Hernández, Y; Espinosa-Juárez, JV; López-Muñoz, FJ; Mena-Valdés, LC, 2021) |
| "In previous animal studies of psychiatric disorders associated with 22q11." | 1.62 | Two novel mouse models mimicking minor deletions in 22q11.2 deletion syndrome revealed the contribution of each deleted region to psychiatric disorders. ( Aiba, A; Funato, H; Koebis, M; Kushima, I; Miyoshi, C; Mori, D; Nakao, K; Ozaki, N; Saito, R; Yanagisawa, M, 2021) |
| "We investigated whether 50-kHz USV playback ameliorates psychomotor deficits induced by haloperidol in a sub-chronic dosing regimen." | 1.56 | Playback of 50-kHz ultrasonic vocalizations overcomes psychomotor deficits induced by sub-chronic haloperidol treatment in rats. ( Melo-Thomas, L; Müller, CP; Schwarting, RKW; Tonelli, LC; Wöhr, M, 2020) |
| "Catalepsy was induced by systemic haloperidol (0." | 1.56 | Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats. ( Ihme, H; Melo-Thomas, L; Schwarting, RKW, 2020) |
| "Subsequently, catalepsy tests were performed again." | 1.51 | Influence of aversive stimulation on haloperidol-induced catalepsy in rats. ( Barroca, NCB; Brandão, ML; Colombo, AC; da Silva, NT; de Oliveira, AR; Guarda, MD; Reimer, AE, 2019) |
| "Fibrosis is a hallmark in the pathogenesis of various diseases, with very limited therapeutic solutions." | 1.51 | High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation. ( Battini, T; Braga, L; Carloni, P; Celsi, F; Collesi, C; Confalonieri, M; Crovella, S; Del Sal, G; Giacca, M; Guarnaccia, C; Kocijan, T; Long, C; Marcello, A; Martinelli, V; Myers, MP; Raspa, M; Rehman, M; Ring, N; Rossetti, G; Skoko, N; Vodret, S; Vukusic, K; Zacchigna, S, 2019) |
| "Haloperidol-induced catalepsy is an animal model of a psychotic disorder that may be associated with neurodegeneration and free radical damage." | 1.51 | Role of Aqueous Extract of the Wood Ear Mushroom, Auricularia polytricha (Agaricomycetes), in Avoidance of Haloperidol-lnduced Catalepsy via Oxidative Stress in Rats. ( Chinnaboina, GK; Gupta, G; Liu, X; Mishra, A; Sharma, RK; Singh, M, 2019) |
| "This study examined the effects of chronic administration of haloperidol in female C57BL/6 mice." | 1.51 | Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment. ( Dawe, GS; Marwari, S, 2019) |
| "Haloperidol is a first-generation antipsychotic used in the treatment of psychoses, especially schizophrenia." | 1.51 | Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. ( Cavalcanti, DMLP; Cavalcanti, JRLP; da Silva, ANA; da Silva, MSM; de Araújo, DP; de Sales, LGP; Guzen, FP; Pinheiro, FI, 2019) |
| "Varenicline is an anti-smoking drug and has the potential to prevent neurodegeneration." | 1.48 | Haloperidol-induced parkinsonism is attenuated by varenicline in mice. ( Gupta, S; Patel, RK; Sharma, AK; Wardhan, N, 2018) |
| "Oxidative stress models, which had Parkinson's disease-like symptoms, were used to evaluate the antioxidant activity of nanoemulsion loaded with selegiline in vivo." | 1.48 | Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ( Ali, J; Baboota, S; Dang, S; Kumar, S; Nigam, K, 2018) |
| " Losartan carboxylic acid (LCA), the potent AT1 blocker metabolite of losartan, suffers from poor bioavailability and brain access." | 1.48 | Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats. ( Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB, 2018) |
| "Depression is a prevalent psychiatric disorder with an increasing impact in global public health." | 1.46 | The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression. ( Alves, ND; Bessa, JM; Correia, JS; Machado-Santos, AR; Mateus-Pinheiro, A; Morais, M; Patrício, P; Pereira, J; Pinto, L; Sousa, N, 2017) |
| " Anesthetized adult female and male rats received either a controlled cortical impact (CCI) or sham injury and then were randomly assigned to a dosing regimen of HAL (0." | 1.46 | Comparable impediment of cognitive function in female and male rats subsequent to daily administration of haloperidol after traumatic brain injury. ( Bondi, CO; de la Tremblaye, PB; Free, KE; Greene, AM; Kline, AE; Lajud, N, 2017) |
| "The ability of DAE to induce catalepsy and enhance haloperidol-induced catalepsy was also investigated in mice." | 1.46 | An ethanolic extract of Desmodium adscendens exhibits antipsychotic-like activity in mice. ( Adjei, S; Amoateng, P; Karikari, TK; Kukuia, KKE; Nyarko, AK; Osei-Safo, D, 2017) |
| "The ability of SNE to cause catalepsy in naïve mice as well as its effect on haloperidol-induced catalepsy was assessed." | 1.46 | Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. ( Adjei, S; Amoateng, P; Bekoe, EO; Karikari, TK; Kombian, SB; Kukuia, KKE; Osei-Safo, D, 2017) |
| "Tardive dyskinesia (TD) is a serious side effect induced by the long-term administration of typical antipsychotics." | 1.43 | Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms. ( An, HM; Kosten, TR; Li, J; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, YC; Wang, ZR; Yang, FD; Zhang, XY; Zhou, DF, 2016) |
| "Domperidone treatment in intact animals evoked a significant increase in normoxic tidal volume, while haloperidol potentiated tidal volume increase in response to hypoxia." | 1.43 | Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease. ( Andrzejewski, K; Budzińska, K; Kaczyńska, K; Zaremba, M, 2016) |
| "Haloperidol can induce catalepsy and this drug effect can be conditioned as well as sensitized to contextual cues." | 1.43 | Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized cata ( Carey, RJ; Carrera, MP; Dias, FRC; Oliveira, LR; Santos, BG; Silva, JLL, 2016) |
| "haloperidol-treated SIR animals." | 1.43 | The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol. ( Cockeran, M; Dreyer, W; Harvey, BH; Sallinen, J; Shahid, M; Uys, M, 2016) |
| "Tardive dyskinesia (TD) is a serious side effect of long-term administration of typical neuroleptics, such as haloperidol." | 1.43 | Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. ( An, HM; Lv, MH; Shi, J; Soares, JC; Tan, YL; Wang, Z; Yang, F; Zhang, XY; Zhou, D, 2016) |
| "Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine." | 1.42 | Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. ( Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B, 2015) |
| "The cause of Parkinsonism has been described as wide and elusive, however, environmental toxins and drugs accounts for large percentage of spontaneous cases in humans." | 1.42 | -NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism. ( Abdulbasit, A; Balogun, WG; Cobham, AE; Enye, LA; Ishola, AO; Nanakumo, ET; Obende, OM; Ogundele, OM, 2015) |
| "A significant reduction of the catalepsy response was seen in rats previously given haloperidol and receiving DBS at the IC." | 1.42 | Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients? ( Melo-Thomas, L; Thomas, U, 2015) |
| "Anhedonia is a relevant symptom in depression and schizophrenia." | 1.42 | Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats. ( De Montis, MG; Ferrari, A; Gambarana, C; Pelliccia, T; Scheggi, S, 2015) |
| " Pharmacokinetic results of CSNE(ROP) in Wistar rat brain and plasma showed a significantly high (p** < 0." | 1.42 | Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. ( Ahuja, A; Al Rohaimi, AH; Ali, J; Baboota, S; Hassan, AA; Muslim, S; Mustafa, G, 2015) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 1.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| " In order to test the hypothesis that the differential blockade of the muscarinic receptor subtypes would influence their potency and efficacy to prevent EPS, here we tested four anticholinergics with varying order of affinities for the muscarinic receptor subtypes, and compared their dose-response curves to inhibit haloperidol-induced catalepsy in male rats." | 1.40 | The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes. ( Alvarez-Cervera, FJ; Bata-García, JL; Erosa-Rivero, HB; Góngora-Alfaro, JL; Heredia-López, FJ, 2014) |
| "They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease." | 1.40 | G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. ( Ferger, B; Hengerer, B; Oeckl, P, 2014) |
| "Five haloperidol-treated animals developed mild TD movements, and no TD was observed in the clozapine group." | 1.40 | Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. ( Blanchet, PJ; Lévesque, D; Mahmoudi, S, 2014) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | 1.40 | Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. ( Fang, Y; Xu, L; Zhang, C, 2014) |
| " To test this hypothesis in a rodent model, the A2A receptor antagonists SCH 412348 (3 mg/kg), vipadenant (10 mg/kg), caffeine (30 mg/kg), or istradefylline (3 mg/kg) were chronically (19-22 days) administered to Sprague Dawley rats, and dyskinetic behaviors were scored across this chronic dosing paradigm." | 1.39 | A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. ( Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E, 2013) |
| " Oral dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i." | 1.39 | Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. ( Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V, 2013) |
| " Physical exercise has been proven to improve gait and locomotor symptoms in Parkinson's disease; we sought to elucidate the effects of physical exercise on PLS induced by chronic administration of haloperidol in rats." | 1.39 | Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats. ( Achaval, M; Baptista, PP; Blank, M; de Senna, PN; do Nascimento, P; Ilha, J; Mestriner, RG; Paim, MF; Saur, L; Vianna, MR; Xavier, LL, 2013) |
| "Haloperidol and vehicle treated male mice heterozygous (HET) or homozygous (HOM) for the mutation, or wild type (WT), were evaluated for open field locomotion, catalepsy duration, pole test performance and rota-rod latency to fall." | 1.38 | Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. ( Broner, EC; Greenbaum, L; Kohn, Y; Lerer, B; Lifschytz, T; Slonimsky, A; Zozulinsky, P, 2012) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| "Sertraline (10 mg/kg ip) was injected either acutely, or over 5 days of repeated treatment." | 1.38 | Effects of sertraline on experimental mouse models of psychosis. ( Bilge, U; Erol, K, 2012) |
| "Rats treated with haloperidol or haloperidol plus NGB 2904 or nafadotride developed catalepsy sensitization with repeated conditioning." | 1.38 | Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904. ( Banasikowski, TJ; Beninger, RJ, 2012) |
| "Histamine was also found to damage the dopaminergic neurons in rat substantia nigra." | 1.38 | Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA. ( Ionov, ID; Severtsev, NN, 2012) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | 1.38 | Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| " Further study is needed to determine whether these results concerning mechanism and dosage can be the basis for prevention of the development of CIS in at risk populations." | 1.38 | Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. ( Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY, 2012) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 1.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| "Haloperidol decanoate was injected to a thigh muscle once every four weeks for 18 weeks." | 1.38 | Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system. ( Ikarashi, Y; Kanno, H; Kase, Y; Sekiguchi, K; Yamaguchi, T, 2012) |
| " In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test." | 1.37 | Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. ( Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M, 2011) |
| " The present study investigates the molecular etiology of haloperidol neurotoxicity and the role of curcumin, a well-known anti-oxidant, in ameliorating these adverse effects." | 1.37 | Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence. ( Bishnoi, M; Chopra, K; Kulkarni, SK; Rongzhu, L, 2011) |
| "Haloperidol is an antipsychotic drug associated with the development of movement disorders." | 1.37 | Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. ( Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Ourique, AF; Pase, CS; Reckziegel, P, 2011) |
| "Here we used the animal models of extrapyramidal disorders cited above, which were performed in two distinct experiments: orofacial dyskinesia (OD)/catalepsy induced by acute reserpine and subchronic haloperidol after (experiment 1) and before (experiment 2) oral treatment with pecan shell aqueous extract (AE), a natural and promissory antioxidant." | 1.37 | Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. ( Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F, 2011) |
| "Haloperidol treatment during pre- and post-natal period affects maternal behavior and this may have long-term effects on the offspring." | 1.37 | The effect of haloperidol on maternal behavior in WAG/Rij rats and its consequences in the offspring. ( Dobryakova, YV; Dubynin, VA; Luijtelaar, GV, 2011) |
| "Rats with liver cirrhosis were more tolerant than normal rats 6 h after bile duct ischemia (P < 0." | 1.37 | Cholangiocytes of cirrhotic rats are more tolerant to ischemia than normal rats: a role for abnormal hepatic arteriovenous communications? ( Jiang, J; Li, DZ; Miao, Y, 2011) |
| " Piglets subjected to hypoxia followed by asphyxic cardiac arrest were treated with saline or two dosing regimens of PPBP after resuscitation." | 1.36 | Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons. ( Carter, EL; Koehler, RC; Martin, LJ; Torbey, MT; Yang, ZJ, 2010) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| " In contrast, acute or chronic administration of MPEP (mGlu5 receptor antagonist) has no anticataleptic action." | 1.35 | Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. ( Amalric, M; Brotchie, JM; Johnston, TH; Lopez, S; Neuville, P; Schann, S; Turle-Lorenzo, N, 2008) |
| "No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD." | 1.35 | Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding. ( Brown, AS; Butler, PD; Keegan, D; Palmer, AA; Rotrosen, J; Siska, LD; Susser, E, 2008) |
| "Haloperidol treatment significantly induced the catalepsy as observed from increased descent time measured in the bar test." | 1.35 | Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. ( Alam, MM; Anwer, T; Azam, F; Barodia, SK, 2009) |
| "Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS)." | 1.35 | Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. ( Barodia, SK; Luthra, PM; Raghubir, R, 2009) |
| "Haloperidol treatment also reduces aggregates formation, an effect that is maintained over time." | 1.35 | Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. ( Betuing, S; Brouillet, E; Caboche, J; Charvin, D; Déglon, N; Deyts, C; Luthi-Carter, R; Pagès, C; Perrin, V; Régulier, E; Roze, E, 2008) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.35 | Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| "Treatment with haloperidol and clozapine attenuated the detrimental performance effects of these challenges, with clozapine exhibiting more robust attenuation." | 1.35 | Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia. ( Martinez, V; Sarter, M, 2008) |
| "The treatment with haloperidol worsened the adverse effects of chronic social stress having effects similar to stress on reward and motivation-related behaviours." | 1.35 | Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. ( Abumaria, N; Flügge, G; Fuchs, E; Havemann-Reinecke, U; Hiemke, C; Rüther, E; Rygula, R; Zernig, G, 2008) |
| "Psychosis is linked to dysregulation of the neuromodulator dopamine and antipsychotic drugs (APDs) work by blocking dopamine receptors." | 1.34 | Linking animal models of psychosis to computational models of dopamine function. ( Becker, S; Kapur, S; Li, M; Smith, AJ, 2007) |
| "Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia." | 1.34 | Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. ( Hashioka, S; Kanba, S; Kato, T; Monji, A, 2007) |
| "Present study was designed to monitor the responsiveness of 5HT (5-Hydroxytryptamine) -2C receptors following the long-term administration of haloperidol in rats." | 1.34 | Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. ( Haleem, DJ; Ikram, H; Samad, N, 2007) |
| " Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits." | 1.34 | The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. ( Feifel, D; Melendez, G; Priebe, K; Shilling, PD, 2007) |
| "Pretreatment with rutin reversed these behavioural changes." | 1.34 | Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2007) |
| " New dopamine D4 receptor agonists, exemplified by (E)-1-(4-chlorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (59a) and (E)-1-(3-chloro-4-fluorophenyl)-3-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one O-methyloxime (64a), exhibited favorable pharmacokinetic profiles and showed oral bioavailability in rat and dog." | 1.33 | 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. ( Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM, 2006) |
| "Mild catalepsy was observed at 30 mg/kg, being more pronounced at 50 mg/kg and 100 mg/kg." | 1.33 | Atypical antipsychotic profile of flunarizine in animal models. ( Dall'Igna, OP; de Oliveira, RV; Fett, P; Gomes, MW; Lara, DR; Mantese, CE; Schuh, J; Souza, DO; Tort, AB, 2005) |
| "Vitamin C enhanced the catalepsy produced by NOS inhibitors and Hal." | 1.33 | Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice. ( Del Bel, EA; Lazzarini, M; Salum, C, 2005) |
| "Schizophrenia is a chronic, debilitating psychotic illness of unknown etiology that has been the subject of many genetic studies." | 1.33 | Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. ( Boffa, E; Kennedy, JL; Likhodi, O; Lipska, BK; Van Tol, HH; Weinberger, DR; Wong, AH, 2005) |
| "MTEP (3 and 5 mg/kg i." | 1.33 | MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wolfarth, S, 2005) |
| "Bradykinesia was also associated with decreased intensity of bursting and amplitude of cross-correlation peaks at rest." | 1.33 | Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity in the rat. ( Hyland, BI; Parr-Brownlie, LC, 2005) |
| "Fluoxetine (1-25 mg/kg) also inhibited catalepsy, although the effect was not dose-dependent; no differences were observed between males and females (5 mg/kg, 180 min: males, 185 +/- 14 vs 712 +/- 14 s in C; females, 169 +/- 10 vs 710 +/- 19 s in C)." | 1.33 | Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. ( Bonikovski, V; Futuro-Neto, HA; Pires, JG, 2005) |
| "Risperidone-treated animals showed a catalepsy-like phenotype, which differed to that of haloperidol-treated rats, indicating that processes other than the anticipated dopaminergic mechanisms are underlying this phenomenon." | 1.33 | Behavioural effects of chronic haloperidol and risperidone treatment in rats. ( Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E, 2006) |
| "When caffeine and adenosine were co-administered, there was no synergistic effect, possibly due to mutual antagonistic effects." | 1.33 | Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2006) |
| "In both experiments, intensification of catalepsy was very stable and was observed 18 days later in haloperidol-treated rats and 101 days later in lesioned animals." | 1.32 | Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. ( Klein, A; Schmidt, WJ, 2003) |
| "At the time of peak hyperalgesia, WIN55,212-2 (1-30mg/kg) or vehicle was administered intraperitoneally and forelimb grip force was measured 0." | 1.32 | A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. ( Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL, 2003) |
| "NMDA-induced convulsions were effectively prevented by both mono- and dications, while only dications were effective against kainate convulsions." | 1.32 | The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. ( Gmiro, VE; Gorbunova, LV; Lukomskaya, NY; Rukoyatkina, NI, 2003) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms." | 1.32 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. ( Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S, 2004) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Haloperidol (HP) has been hypothesized to potentiate increases in oxidative stress or free radical-mediated levels of toxic metabolites in rat striatum while simultaneous upregulating dopamine (DA)-D2 receptors leading to presumed DA supersensitivity." | 1.32 | Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. ( Fairfax, DF; Gupta, SK; Henry, P; Khan, RF; Mishra, RK; N-Marandi, S; Rogoza, RM, 2004) |
| " A pilot dose-response study investigated an intracranial approach of topically applying endothelin-1 (ET-1) to the M2 portion of the middle cerebral artery in a small sample of marmosets for up to 6 hours (n = 2 or 3 per group)." | 1.32 | A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset. ( David, C; Elliott, H; Farnfield, B; Golder, J; Hadingham, SJ; Hunter, AJ; Parsons, AA; Roberts, JC; Virley, D; Whelan, G, 2004) |
| "Catalepsy, a symptom of Parkinson's disease and related disorders can be produced in rats and other laboratory animals by the blockade of nigrostriatal dopamine using dopaminergic antagonists such as haloperidol." | 1.31 | Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats. ( Field, EF; Pellis, SM; Whishaw, IQ, 2000) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 1.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| " We also provide evidence of deficient NT neurotransmission as well as a left-shifted antipsychotic drug dose-response curve in isolation-reared rats." | 1.31 | Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. ( Binder, EB; Kilts, CD; Kinkead, B; Nemeroff, CB; Owens, MJ, 2001) |
| "Treatment with amphetamine induced decrease of GAP-43 mRNA expression, that was detected also during recovery period, up to 14 days after the last day of 7 days treatments." | 1.31 | Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43. ( Kanazir, S; Rakic, L; Ruzdijic, S; Veskov, R; Vukosavic, S, 2001) |
| "The heatstroke was induced by exposing the urethane-anesthetized rats to an ambient temperature of 42 degrees C." | 1.31 | The protective effect of hypervolemic hemodilution in experimental heatstroke. ( Chang, CK; Chien, CH; Chou, HL; Lin, MT, 2001) |
| "Striatal neurons in symptomatic Huntington's disease (HD) transgenic mice are resistant to a variety of toxic insults, including quinolinic acid (QA), kainic acid and 3-nitropropionic acid." | 1.31 | Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. ( Costain, WJ; Crocker, SF; Denovan-Wright, EM; Hamilton, LC; MacGibbon, GA; Murphy, KM; Robertson, HA, 2002) |
| "Haloperidol-induced TD was also attenuated by the antioxidant, vitamin E (400 and 800 mg/kg, p." | 1.31 | Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia. ( Bhattacharya, D; Bhattacharya, SK; Ghosal, S; Sairam, K, 2002) |
| "Haloperidol and clozapine were tested in rats after daily administration for 3 and 21 days in combination with vehicle or PCP (2." | 1.30 | A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. ( Sams-Dodd, F, 1998) |
| " After chronic haloperidol dosing (vehicle, 0." | 1.30 | Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism. ( Fowler, SC; Wang, G, 1998) |
| "Haloperidol treatment for 34 weeks increased the optical density of preproenkephalin messenger RNA in individual striatal neurons and enkephalin peptide in the neuropil, regardless of the level of oral dyskinesia produced." | 1.30 | The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. ( Andreassen, OA; Finsen, B; Jørgensen, HA; Ostergaard, K; Sørensen, JC; West, MJ, 1999) |
| "This "injection-conditioned catalepsy" was also observed after repeated treatment with the dopamine D2 antagonists, haloperidol and metoclopramide." | 1.30 | Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice. ( Chinen, CC; Frussa-Filho, R, 1999) |
| "However, the severity of the catalepsy score following the third through seventh injections of haloperidol strongly correlated with the concurrent number of VCMs." | 1.29 | Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. ( Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ, 1995) |
| " However, when neuronal sampling was performed in unanesthetized rats, chronic administration of haloperidol (daily for 21-28 days) failed to reduce the incidence of active dopaminergic neurons." | 1.29 | Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. ( Diana, M; Gessa, GL; Lilliu, V; Mereu, G; Muntoni, AL; Vargiu, P, 1994) |
| "Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1." | 1.29 | Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. ( Friedman, MB; Gao, XM; Kakigi, T; Tamminga, CA, 1994) |
| " Chronic administration of the selective serotonin re-uptake inhibitors fluoxetine and clomipramine (CMI) at 5 mg/kg per day and fluvoxamine at 10 mg/kg twice a day significantly decreased schedule-induced polydipsia (SIP) on day 15 and throughout the remainder of the study compared to control rats." | 1.29 | Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. ( Corbett, R; Cornfeldt, M; Dunn, RW; Smith, C; Szewczak, M; Woods, A, 1993) |
| "With 40 rabbits, the occurrence of convulsion at this dose level was 100%." | 1.29 | [Intracerebral-ventricular injection of 4-aminopyridine induced convulsion in rabbits]. ( Cao, H; Xu, JH; Zheng, JH, 1993) |
| "Neither (-)-3-PPP nor SND 919 produced dystonia, but had observable dopamine D2 receptor agonistic effects, (-)-3-PPP producing emesis at 1-4 mg/kg and SND 919 producing motoric unrest and stereotypy at 0." | 1.29 | Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. ( Gerlach, J; Peacock, L, 1993) |
| "Haloperidol was injected in doses of 0." | 1.29 | Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. ( Lorenc-Koci, E; Ossowska, K; Wolfarth, S, 1996) |
| "Haloperidol-induced VC were inhibited by the s." | 1.28 | Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. ( Collu, M; Diana, M; Gessa, GL; Mura, A, 1992) |
| "In haloperidol-treated epileptic rats, LCMRglc decreased to levels comparable to those measured in untreated control rats." | 1.28 | Mapping of cerebral energy metabolism in rats with genetic generalized nonconvulsive epilepsy. ( Boyet, S; Marescaux, C; Nehlig, A; Vergnes, M, 1992) |
| "Treatment with haloperidol (0." | 1.28 | Drug-induced purposeless chewing: animal model of dyskinesia or nausea? ( Iversen, SD; Rupniak, NM; Tye, SJ, 1990) |
| "2." | 1.28 | Differential modulation of mouse brain biogenic amines by haloperidol and pimozide: implications in Tourette's syndrome. ( Messiha, FS, 1990) |
| "The chlorpromazine group was similar to the haloperidol group." | 1.28 | Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior. ( Miyamoto, K, 1990) |
| "Pretreatment with bromocriptine conferred no protection against the syndrome." | 1.28 | Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome? ( Keck, PE; McElroy, SL; Pope, HG; Seeler, DC, 1990) |
| " Long-term administration induced distinctively different patterns of oral activity in the three drug groups, both in number of CSMs and the form of these movements." | 1.28 | Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. ( Ellison, G; See, RE, 1990) |
| " This phenomenon, probably due to the inhibition of the striato-nigral GABA-ergic pathway, could serve as an easy and reliable model for the human tardive dyskinesias dues to the chronic administration of neuroleptics." | 1.28 | [Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man]. ( Vamvakides, A, 1989) |
| "Haloperidol treatment significantly increased striatal gamma-aminobutyric acid content and glutamic acid decarboxylase activity by 17% and 16% respectively." | 1.27 | Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined. ( Lapierre, YD; Rastogi, RB; Rastogi, SK; Singhal, RL, 1983) |
| "Treatment with molindone for 14 days at 3, 6, 20 and 40 mg/kg, enhanced the stereotyped behavioral response induced by apomorphine and increased the numbered of D-2 dopamine receptors in the striatum (Bmax) labelled by high affinity (Kd = 40 pmol) binding or [3H] spiroperidol in the guinea-pig." | 1.27 | Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia. ( Curtin, J; Fields, J; Koller, W, 1984) |
| " An experimental study of the long-term administrations of haloperidol revealed the formation of adaptation to the drug which can be overcome by a zigzag-like sharp elevation of the dosage followed by rapid reduction to the baseline level." | 1.27 | [Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)]. ( Allikmets, LKh; Avrutskiĭ, GIa; Beliakov, AV; Neduva, AA; Zharkovskiĭ, AM, 1984) |
| "Petechiae were not seen below the diaphragm." | 1.27 | Norepinephrine-induced pulmonary petechiae in the rat: an experimental model with potential implications for sudden infant death syndrome. ( Catron, AC; Farber, JP; Krous, HF, 1984) |
| "In ongoing studies of chronic administration of neuroleptics to monkeys (Cebus apella) and rats, the regional distribution of glutamic acid decarboxylase (GAD) and brain levels of homovanillic acid were examined." | 1.27 | Experimental tardive dyskinesia. ( Gunne, LM; Häggström, JE, 1985) |
| "Haloperidol was given first in doses of 1." | 1.27 | Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review. ( Domino, EF, 1985) |
| "Convulsive seizure was suppressed by physostigmine (p less than 0." | 1.27 | [The influences of neurotransmitters on the traumatic unconsciousness, immediate convulsion and mortality in the experimental mice model]. ( Hashizume, K; Manaka, S; Sasaki, M; Takakura, K, 1987) |
| " Subacute and chronic administration of imipramine (4 or 15 mg/kg) decreased immobility of rats in the behavioral despair model." | 1.27 | The effects of carbamazepine on two animal models of depression. ( Barros, HM; Leite, JR, 1987) |
| "Rats with ablated frontal sensorimotor cortex and one with ablated sensorimotor connections to forebrain showed more vacuous chewing movements following 6-week chronic administration of a neuroleptic than did occipitally damaged rats or normal controls who were treated in the same way." | 1.26 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. ( Glassman, HN; Glassman, RB, 1980) |
| "The syndrome was not seen after thioridazine (3-7 mg/kg)." | 1.26 | Acute dystonia as an idiosyncratic response to neuroleptics in baboons. ( Anlezark, GM; Marsden, CD; Meldrum, BS, 1977) |
| "We conclude that phenytoin induced hyperkinesias reflect a specific effect of phenytoin on an abnormal neural substrate and suggest the presence of an otherwise silent pathological alteration of the corpus striatum." | 1.26 | Clinical and experimental studies of phenytoin-induced hyperkinesias. ( Klawans, HL; Koller, WC; Nausieda, PA; Weiner, WJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 63 (12.21) | 18.7374 |
| 1990's | 70 (13.57) | 18.2507 |
| 2000's | 158 (30.62) | 29.6817 |
| 2010's | 191 (37.02) | 24.3611 |
| 2020's | 34 (6.59) | 2.80 |
| Authors | Studies |
|---|---|
| Bagli, J | 1 |
| Bogri, T | 1 |
| Voith, K | 1 |
| Talaga, P | 1 |
| Matagne, A | 1 |
| Klitgaard, H | 1 |
| Kolasa, T | 1 |
| Matulenko, MA | 1 |
| Hakeem, AA | 1 |
| Patel, MV | 1 |
| Mortell, K | 1 |
| Bhatia, P | 1 |
| Henry, R | 1 |
| Nakane, M | 1 |
| Hsieh, GC | 2 |
| Terranova, MA | 1 |
| Uchic, ME | 1 |
| Miller, LN | 1 |
| Chang, R | 1 |
| Donnelly-Roberts, DL | 1 |
| Namovic, MT | 1 |
| Hollingsworth, PR | 1 |
| Martino, B | 1 |
| El Kouhen, O | 1 |
| Marsh, KC | 2 |
| Wetter, JM | 2 |
| Moreland, RB | 1 |
| Brioni, JD | 2 |
| Stewart, AO | 1 |
| Sekhar, KV | 1 |
| Rao, VS | 1 |
| Devambatla, RKV | 1 |
| Kumar, MM | 1 |
| Liu, H | 1 |
| Altenbach, RJ | 1 |
| Carr, TL | 1 |
| Chandran, P | 1 |
| Lewis, LG | 1 |
| Manelli, AM | 1 |
| Milicic, I | 1 |
| Miller, TR | 1 |
| Strakhova, MI | 1 |
| Vortherms, TA | 1 |
| Wakefield, BD | 1 |
| Witte, DG | 1 |
| Honore, P | 1 |
| Esbenshade, TA | 1 |
| Cowart, MD | 1 |
| Rotella, DP | 2 |
| McFarlane, GR | 1 |
| Greenfield, A | 1 |
| Grosanu, C | 1 |
| Robichaud, AJ | 2 |
| Denny, RA | 1 |
| Feenstra, RW | 1 |
| Núñez-García, S | 1 |
| Reinders, JH | 2 |
| Neut, Mv | 1 |
| McCreary, A | 1 |
| Kruse, CG | 2 |
| Sullivan, K | 1 |
| Pruthi, F | 1 |
| Lai, M | 2 |
| Zhang, J | 3 |
| Kowal, DM | 2 |
| Carrick, T | 2 |
| Grauer, SM | 1 |
| Navarra, RL | 1 |
| Graf, R | 1 |
| Brennan, J | 1 |
| Marquis, KL | 2 |
| Pausch, MH | 2 |
| Yan, Y | 1 |
| Zhou, P | 1 |
| Feenstra, R | 1 |
| van der Neut, M | 1 |
| Banerjee, A | 1 |
| Patil, S | 1 |
| Pawar, MY | 1 |
| Gullapalli, S | 1 |
| Gupta, PK | 1 |
| Gandhi, MN | 1 |
| Bhateja, DK | 1 |
| Bajpai, M | 1 |
| Sangana, RR | 1 |
| Gudi, GS | 1 |
| Khairatkar-Joshi, N | 1 |
| Gharat, LA | 1 |
| Zagórska, A | 2 |
| Kołaczkowski, M | 2 |
| Bucki, A | 2 |
| Siwek, A | 2 |
| Kazek, G | 1 |
| Satała, G | 1 |
| Bojarski, AJ | 1 |
| Partyka, A | 2 |
| Wesołowska, A | 2 |
| Pawłowski, M | 2 |
| Cao, X | 1 |
| Chen, Y | 2 |
| Zhang, Y | 2 |
| Lan, Y | 1 |
| Xu, X | 2 |
| Qiu, Y | 1 |
| Zhao, S | 1 |
| Liu, X | 2 |
| Liu, BF | 1 |
| Zhang, G | 1 |
| Gunia-Krzyżak, A | 1 |
| Żelaszczyk, D | 1 |
| Rapacz, A | 1 |
| Żesławska, E | 1 |
| Waszkielewicz, AM | 1 |
| Pańczyk, K | 1 |
| Słoczyńska, K | 1 |
| Pękala, E | 2 |
| Nitek, W | 1 |
| Filipek, B | 1 |
| Marona, H | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Czopek, A | 1 |
| Drop, M | 1 |
| Głuch-Lutwin, M | 1 |
| Chrzanowska, A | 1 |
| Struga, M | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Yan, W | 1 |
| Fan, L | 1 |
| Yu, J | 1 |
| Liu, R | 1 |
| Wang, H | 2 |
| Tan, L | 1 |
| Wang, S | 3 |
| Cheng, J | 1 |
| Kurimoto, E | 1 |
| Yamada, R | 1 |
| Hirakawa, T | 1 |
| Kimura, H | 2 |
| Lages, YV | 1 |
| Maisonnette, SS | 1 |
| Rosseti, FP | 1 |
| Galvão, BO | 1 |
| Landeira-Fernandez, J | 1 |
| Léa Blondelle, KD | 1 |
| Simplice, FH | 1 |
| Hervé Hervé, NA | 1 |
| Eglantine, KW | 1 |
| Roland, RN | 1 |
| Jorelle Linda, DK | 1 |
| Balbine, KN | 1 |
| Simon Désiré, GN | 1 |
| Guillaume, CW | 1 |
| Alin, C | 1 |
| Saleem, U | 5 |
| Khalid, S | 3 |
| Chauhdary, Z | 3 |
| Anwar, F | 6 |
| Shah, MA | 3 |
| Alsharif, I | 3 |
| Babalghith, AO | 3 |
| Khayat, RO | 3 |
| Albalawi, AE | 3 |
| Baokbah, TAS | 3 |
| Farrukh, M | 3 |
| Vargas-De-La-Cruz, C | 3 |
| Panichayupakaranant, P | 3 |
| Kotliarova, A | 2 |
| Podturkina, AV | 2 |
| Pavlova, AV | 3 |
| Gorina, DS | 2 |
| Lastovka, AV | 2 |
| Ardashov, OV | 3 |
| Rogachev, AD | 2 |
| Izyurov, AE | 2 |
| Arefieva, AB | 2 |
| Kulikov, AV | 2 |
| Tolstikova, TG | 3 |
| Volcho, KP | 3 |
| Salakhutdinov, NF | 3 |
| Sidorova, Y | 2 |
| Szocsics, P | 1 |
| Papp, P | 1 |
| Havas, L | 1 |
| Lőke, J | 1 |
| Maglóczky, Z | 1 |
| Valvassori, SS | 1 |
| da Rosa, RT | 1 |
| Dal-Pont, GC | 1 |
| Varela, RB | 1 |
| Mastella, GA | 1 |
| Daminelli, T | 1 |
| Fries, GR | 1 |
| Quevedo, J | 2 |
| Zugno, AI | 1 |
| Kitagawa, K | 1 |
| Nagai, T | 1 |
| Yamada, K | 1 |
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Hussain, S | 1 |
| Villarreal, S | 1 |
| Ramirez, N | 1 |
| Hussain, A | 1 |
| Sumaya, IC | 1 |
| Raza, Z | 1 |
| Chaudary, Z | 1 |
| Ahmad, B | 2 |
| Bhattamisra, SK | 1 |
| Shak, AT | 1 |
| Xi, LW | 1 |
| Safian, NH | 1 |
| Choudhury, H | 1 |
| Lim, WM | 1 |
| Shahzad, N | 1 |
| Alhakamy, NA | 1 |
| Anwer, MK | 1 |
| Radhakrishnan, AK | 1 |
| Md, S | 1 |
| Correa, M | 2 |
| Pardo, M | 1 |
| Carratalá-Ros, C | 1 |
| Martínez-Verdú, A | 1 |
| Salamone, JD | 3 |
| Stark, T | 2 |
| Di Bartolomeo, M | 1 |
| Di Marco, R | 1 |
| Drazanova, E | 1 |
| Platania, CBM | 1 |
| Iannotti, FA | 1 |
| Ruda-Kucerova, J | 3 |
| D'Addario, C | 1 |
| Kratka, L | 1 |
| Pekarik, V | 1 |
| Piscitelli, F | 1 |
| Babinska, Z | 2 |
| Fedotova, J | 1 |
| Giurdanella, G | 1 |
| Salomone, S | 1 |
| Sulcova, A | 1 |
| Bucolo, C | 1 |
| Wotjak, CT | 1 |
| Starcuk, Z | 1 |
| Drago, F | 1 |
| Mechoulam, R | 1 |
| Di Marzo, V | 1 |
| Micale, V | 3 |
| Melo-Thomas, L | 6 |
| Tonelli, LC | 3 |
| Müller, CP | 2 |
| Wöhr, M | 3 |
| Schwarting, RKW | 3 |
| Zhao, L | 1 |
| Cheng, N | 1 |
| Sun, B | 1 |
| Li, A | 2 |
| Wang, Z | 4 |
| Wang, Y | 1 |
| Qi, F | 1 |
| Okada, T | 1 |
| Shioda, K | 1 |
| Makiguchi, A | 1 |
| Suda, S | 1 |
| Sanawar, M | 1 |
| Nazir, S | 1 |
| Akhtar, MF | 1 |
| Ismail, T | 1 |
| Horska, K | 2 |
| Kotolova, H | 1 |
| Karpisek, M | 1 |
| Hammer, T | 1 |
| Prochazka, J | 1 |
| Zemba Cilic, A | 1 |
| Zemba, M | 1 |
| Cilic, M | 1 |
| Balenovic, I | 1 |
| Strbe, S | 1 |
| Ilic, S | 1 |
| Vukojevic, J | 1 |
| Zoricic, Z | 1 |
| Filipcic, I | 1 |
| Kokot, A | 1 |
| Drmic, D | 1 |
| Blagaic, AB | 1 |
| Tvrdeic, A | 1 |
| Seiwerth, S | 2 |
| Sikiric, P | 2 |
| Déciga-Campos, M | 1 |
| Villafán-Gutiérrez, R | 1 |
| Espinosa-Juárez, JV | 2 |
| Jaramillo-Morales, OA | 1 |
| López-Muñoz, FJ | 2 |
| Kucera, J | 1 |
| Hruska, P | 1 |
| Kuruczova, D | 1 |
| Bienertova-Vasku, J | 1 |
| Ihme, H | 1 |
| Mena-Valdés, LC | 1 |
| Blanco-Hernández, Y | 1 |
| Wang, MH | 2 |
| Yang, CC | 1 |
| Tseng, HC | 2 |
| Fang, CH | 1 |
| Lin, YW | 1 |
| Soung, HS | 2 |
| Kent, CN | 1 |
| Fulton, MG | 1 |
| Stillwell, KJ | 1 |
| Dickerson, JW | 2 |
| Loch, MT | 2 |
| Rodriguez, AL | 2 |
| Blobaum, AL | 3 |
| Boutaud, O | 1 |
| Rook, JL | 1 |
| Niswender, CM | 4 |
| Conn, PJ | 4 |
| Lindsley, CW | 3 |
| Waku, I | 1 |
| Magalhães, MS | 1 |
| Alves, CO | 1 |
| de Oliveira, AR | 2 |
| Saito, R | 1 |
| Miyoshi, C | 1 |
| Koebis, M | 1 |
| Kushima, I | 1 |
| Nakao, K | 1 |
| Mori, D | 1 |
| Ozaki, N | 1 |
| Funato, H | 1 |
| Yanagisawa, M | 1 |
| Aiba, A | 1 |
| Varga, TG | 1 |
| de Toledo Simões, JG | 1 |
| Siena, A | 1 |
| Henrique, E | 1 |
| da Silva, RCB | 1 |
| Dos Santos Bioni, V | 1 |
| Ramos, AC | 1 |
| Rosenstock, TR | 1 |
| Patergnani, S | 1 |
| Bonora, M | 1 |
| Ingusci, S | 1 |
| Previati, M | 1 |
| Marchi, S | 1 |
| Zucchini, S | 2 |
| Perrone, M | 1 |
| Wieckowski, MR | 1 |
| Castellazzi, M | 1 |
| Pugliatti, M | 1 |
| Giorgi, C | 1 |
| Simonato, M | 2 |
| Pinton, P | 1 |
| Potnuri, AG | 1 |
| Reddy, KP | 1 |
| Suresh, P | 1 |
| Husain, GM | 1 |
| Kazmi, MH | 1 |
| Harishankar, N | 1 |
| Samad, N | 6 |
| Haleem, DJ | 8 |
| Akintunde, JK | 1 |
| Abubakar, OK | 1 |
| Morais, M | 1 |
| Patrício, P | 1 |
| Mateus-Pinheiro, A | 1 |
| Alves, ND | 1 |
| Machado-Santos, AR | 1 |
| Correia, JS | 1 |
| Pereira, J | 1 |
| Pinto, L | 1 |
| Sousa, N | 1 |
| Bessa, JM | 1 |
| Free, KE | 2 |
| Greene, AM | 1 |
| Bondi, CO | 2 |
| Lajud, N | 1 |
| de la Tremblaye, PB | 1 |
| Kline, AE | 2 |
| Amoateng, P | 2 |
| Adjei, S | 2 |
| Osei-Safo, D | 2 |
| Kukuia, KKE | 2 |
| Karikari, TK | 2 |
| Nyarko, AK | 1 |
| Bekoe, EO | 1 |
| Kombian, SB | 1 |
| Hara, Y | 1 |
| Ago, Y | 1 |
| Taruta, A | 1 |
| Hasebe, S | 1 |
| Kawase, H | 1 |
| Tanabe, W | 1 |
| Tsukada, S | 1 |
| Nakazawa, T | 1 |
| Hashimoto, H | 2 |
| Matsuda, T | 1 |
| Takuma, K | 1 |
| Alachkar, A | 2 |
| Wang, L | 3 |
| Yoshimura, R | 1 |
| Hamzeh, AR | 1 |
| Sanathara, N | 2 |
| Lee, SM | 1 |
| Abbott, GW | 1 |
| Civelli, O | 2 |
| Ning, H | 1 |
| Cao, D | 1 |
| Kang, B | 1 |
| Xie, S | 1 |
| Meng, Y | 1 |
| Schwarting, R | 2 |
| Obi, K | 1 |
| Amano, I | 1 |
| Takatsuru, Y | 1 |
| Cheng, JP | 1 |
| Leary, JB | 1 |
| O'Neil, DA | 1 |
| Meyer, EA | 1 |
| Lei, K | 1 |
| He, GF | 1 |
| Zhang, CL | 1 |
| Liu, YN | 1 |
| Li, J | 5 |
| He, GZ | 1 |
| Li, XP | 2 |
| Ren, XH | 1 |
| Liu, D | 1 |
| Vikhe, S | 1 |
| Nirmal, S | 1 |
| Chen, CN | 1 |
| Chang, KC | 1 |
| Engelhardt, KA | 1 |
| Marchetta, P | 1 |
| Suzuki, K | 1 |
| Harada, A | 1 |
| Suzuki, H | 1 |
| Capuani, C | 1 |
| Ugolini, A | 1 |
| Corsi, M | 1 |
| Ben-Azu, B | 1 |
| Aderibigbe, AO | 1 |
| Ajayi, AM | 1 |
| Eneni, AO | 1 |
| Umukoro, S | 1 |
| Iwalewa, EO | 1 |
| Sharma, AK | 2 |
| Gupta, S | 1 |
| Patel, RK | 1 |
| Wardhan, N | 1 |
| Nespoli, E | 1 |
| Rizzo, F | 1 |
| Boeckers, T | 1 |
| Schulze, U | 1 |
| Hengerer, B | 2 |
| Kumar, S | 1 |
| Dang, S | 1 |
| Nigam, K | 1 |
| Ali, J | 2 |
| Baboota, S | 2 |
| Kumbol, VW | 1 |
| Abotsi, WKM | 1 |
| Ekuadzi, E | 1 |
| Woode, E | 1 |
| Uzuneser, TC | 1 |
| Schindehütte, M | 1 |
| Dere, E | 1 |
| von Hörsten, S | 1 |
| Kornhuber, J | 1 |
| Grömer, TW | 1 |
| Sonnenschein, SF | 1 |
| Gill, KM | 2 |
| Grace, AA | 2 |
| Kurauchi, Y | 1 |
| Yoshimaru, Y | 1 |
| Kajiwara, Y | 1 |
| Yamada, T | 1 |
| Matsuda, K | 1 |
| Hisatsune, A | 1 |
| Seki, T | 1 |
| Katsuki, H | 1 |
| Subudhi, BB | 1 |
| Sahu, PK | 1 |
| Singh, VK | 1 |
| Prusty, S | 1 |
| Hailwood, JM | 1 |
| Heath, CJ | 1 |
| Phillips, BU | 1 |
| Robbins, TW | 1 |
| Saksida, LM | 1 |
| Bussey, TJ | 1 |
| Monte, GG | 1 |
| Nani, JV | 1 |
| de Almeida Campos, MR | 1 |
| Dal Mas, C | 1 |
| Marins, LAN | 1 |
| Martins, LG | 1 |
| Tasic, L | 1 |
| Mori, MA | 1 |
| Hayashi, MAF | 1 |
| Barroca, NCB | 1 |
| Guarda, MD | 1 |
| da Silva, NT | 1 |
| Colombo, AC | 1 |
| Reimer, AE | 1 |
| Brandão, ML | 1 |
| Takahashi, K | 1 |
| Nakagawasai, O | 1 |
| Sakuma, W | 1 |
| Nemoto, W | 1 |
| Odaira, T | 1 |
| Lin, JR | 1 |
| Onogi, H | 1 |
| Srivastava, LK | 1 |
| Tan-No, K | 1 |
| Rehman, M | 1 |
| Vodret, S | 1 |
| Braga, L | 1 |
| Guarnaccia, C | 1 |
| Celsi, F | 1 |
| Rossetti, G | 1 |
| Martinelli, V | 1 |
| Battini, T | 1 |
| Long, C | 1 |
| Vukusic, K | 1 |
| Kocijan, T | 1 |
| Collesi, C | 1 |
| Ring, N | 1 |
| Skoko, N | 1 |
| Giacca, M | 1 |
| Del Sal, G | 1 |
| Confalonieri, M | 1 |
| Raspa, M | 1 |
| Marcello, A | 1 |
| Myers, MP | 1 |
| Crovella, S | 1 |
| Carloni, P | 1 |
| Zacchigna, S | 1 |
| Sharma, RK | 1 |
| Mishra, A | 1 |
| Chinnaboina, GK | 1 |
| Gupta, G | 2 |
| Singh, M | 1 |
| Marwari, S | 1 |
| Dawe, GS | 2 |
| Fry, BR | 1 |
| Russell, N | 1 |
| Gifford, R | 1 |
| Robles, CF | 1 |
| Manning, CE | 1 |
| Sawa, A | 2 |
| Niwa, M | 1 |
| Johnson, AW | 1 |
| Cadeddu, R | 1 |
| Bäckström, T | 1 |
| Floris, G | 1 |
| Nordkild, P | 1 |
| Segerdahl, M | 1 |
| Bortolato, M | 3 |
| Jensen, R | 1 |
| Guzen, FP | 1 |
| Cavalcanti, JRLP | 1 |
| Cavalcanti, DMLP | 1 |
| de Sales, LGP | 1 |
| da Silva, MSM | 1 |
| da Silva, ANA | 1 |
| Pinheiro, FI | 1 |
| de Araújo, DP | 1 |
| Foute Nelong, T | 1 |
| Manduca, JD | 1 |
| Zonneveld, PM | 1 |
| Perreault, ML | 1 |
| Tsuchie, K | 1 |
| Miyaoka, T | 1 |
| Furuya, M | 1 |
| Liaury, K | 1 |
| Ieda, M | 1 |
| Wake, R | 1 |
| Horiguchi, J | 1 |
| Takechi, M | 1 |
| Kondo, MA | 1 |
| Tajinda, K | 1 |
| Colantuoni, C | 1 |
| Hiyama, H | 1 |
| Seshadri, S | 1 |
| Huang, B | 1 |
| Pou, S | 1 |
| Furukori, K | 1 |
| Hookway, C | 1 |
| Jaaro-Peled, H | 1 |
| Kano, SI | 1 |
| Matsuoka, N | 2 |
| Harada, K | 1 |
| Ni, K | 1 |
| Pevsner, J | 1 |
| Telegdy, G | 2 |
| Adamik, A | 1 |
| Jones, N | 1 |
| Bleickardt, C | 1 |
| Mullins, D | 1 |
| Parker, E | 1 |
| Hodgson, R | 1 |
| Grover, S | 1 |
| Kumar, P | 1 |
| Singh, K | 1 |
| Vikram, V | 1 |
| Budhiraja, RD | 1 |
| An, HM | 4 |
| Tan, YL | 4 |
| Shi, J | 4 |
| Wang, ZR | 3 |
| Wang, YC | 3 |
| Kosten, TR | 2 |
| Zhou, DF | 2 |
| Yang, FD | 3 |
| Zhang, XY | 4 |
| Voronkov, DN | 1 |
| Khudoerkov, RM | 1 |
| Dovedova, EL | 1 |
| Crowley, JJ | 1 |
| Ashraf-Khorassani, M | 1 |
| Castagnoli, N | 1 |
| Sullivan, PF | 1 |
| Bleickardt, CJ | 1 |
| Kazdoba, TM | 1 |
| Jones, NT | 1 |
| Hunter, JC | 2 |
| Hodgson, RA | 2 |
| Herrera-Meza, G | 1 |
| Manzo, J | 1 |
| Hernández, ME | 1 |
| Miquel, M | 1 |
| García, LI | 1 |
| Marinho, EA | 1 |
| Oliveira-Lima, AJ | 1 |
| Wuo-Silva, R | 1 |
| Santos, R | 1 |
| Baldaia, MA | 1 |
| Hollais, AW | 1 |
| Longo, BM | 1 |
| Berro, LF | 1 |
| Frussa-Filho, R | 4 |
| Konieczny, J | 3 |
| Lenda, T | 1 |
| Ishiwari, K | 1 |
| Conway, MW | 1 |
| Francois, J | 1 |
| Huxter, J | 1 |
| Lowry, JP | 1 |
| Schwarz, AJ | 1 |
| Tricklebank, M | 1 |
| Gilmour, G | 1 |
| Magaji, MG | 1 |
| Mohammed, M | 1 |
| Magaji, RA | 1 |
| Musa, AM | 1 |
| Abdu-Aguye, I | 1 |
| Hussaini, IM | 1 |
| Cook, JM | 1 |
| Poe, MM | 1 |
| Erosa-Rivero, HB | 1 |
| Bata-García, JL | 1 |
| Alvarez-Cervera, FJ | 1 |
| Heredia-López, FJ | 1 |
| Góngora-Alfaro, JL | 1 |
| Oeckl, P | 1 |
| Ferger, B | 2 |
| Röpke, J | 1 |
| Busanello, A | 1 |
| Leal, CQ | 1 |
| de Moraes Reis, E | 1 |
| de Freitas, CM | 1 |
| Villarinho, JG | 2 |
| Figueira, FH | 1 |
| Mello, CF | 1 |
| Ferreira, J | 2 |
| Fachinetto, R | 3 |
| Mahmoudi, S | 1 |
| Lévesque, D | 2 |
| Blanchet, PJ | 1 |
| Tournier, BB | 1 |
| Ginovart, N | 1 |
| Gubellini, P | 3 |
| Melon, C | 3 |
| Dale, E | 1 |
| Doller, D | 2 |
| Kerkerian-Le Goff, L | 3 |
| Santoro, ML | 2 |
| Ota, VK | 2 |
| Stilhano, RS | 1 |
| Silva, PN | 1 |
| Santos, CM | 2 |
| Diana, MC | 2 |
| Gadelha, A | 1 |
| Bressan, RA | 2 |
| Melaragno, MI | 1 |
| Han, SW | 1 |
| Abílio, VC | 3 |
| Belangero, SI | 2 |
| Wegleiter, K | 1 |
| Hermann, M | 1 |
| Posod, A | 1 |
| Wechselberger, K | 1 |
| Stanika, RI | 1 |
| Obermair, GJ | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Urbanek, M | 1 |
| Griesmaier, E | 1 |
| Palotai, M | 1 |
| Tanaka, M | 1 |
| Bagosi, Z | 1 |
| Jászberényi, M | 1 |
| Kasture, SB | 1 |
| Gaikar, M | 1 |
| Kasture, V | 1 |
| Arote, S | 1 |
| Salve, B | 1 |
| Rosas, M | 1 |
| Cotti, E | 1 |
| Acquas, E | 1 |
| Shireen, E | 1 |
| Pervez, S | 1 |
| Masroor, M | 1 |
| Ali, WB | 1 |
| Rais, Q | 1 |
| Khalil, S | 1 |
| Tariq, A | 1 |
| Zhang, C | 1 |
| Fang, Y | 1 |
| Xu, L | 1 |
| Zhang, F | 3 |
| Ouhaz, Z | 1 |
| Ba-M'hamed, S | 1 |
| Bennis, M | 1 |
| Kawaura, K | 1 |
| Koike, H | 1 |
| Kinoshita, K | 1 |
| Kambe, D | 1 |
| Kaku, A | 1 |
| Karasawa, J | 1 |
| Chaki, S | 1 |
| Hikichi, H | 1 |
| Hagino, Y | 1 |
| Kasai, S | 1 |
| Fujita, M | 1 |
| Setogawa, S | 1 |
| Yamaura, H | 1 |
| Yanagihara, D | 1 |
| Hashimoto, M | 1 |
| Kobayashi, K | 2 |
| Meltzer, HY | 3 |
| Ikeda, K | 1 |
| Ogundele, OM | 1 |
| Nanakumo, ET | 1 |
| Ishola, AO | 1 |
| Obende, OM | 1 |
| Enye, LA | 1 |
| Balogun, WG | 1 |
| Cobham, AE | 1 |
| Abdulbasit, A | 1 |
| Citraro, R | 1 |
| Leo, A | 1 |
| Aiello, R | 1 |
| Pugliese, M | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Thomas, U | 1 |
| Oyamada, Y | 1 |
| Horiguchi, M | 2 |
| Rajagopal, L | 1 |
| Miyauchi, M | 1 |
| van der Sluis, RJ | 1 |
| Nahon, JE | 1 |
| Reuwer, AQ | 1 |
| Van Eck, M | 1 |
| Hoekstra, M | 1 |
| Scheggi, S | 1 |
| Pelliccia, T | 1 |
| Ferrari, A | 1 |
| De Montis, MG | 1 |
| Gambarana, C | 1 |
| Hall, BJ | 1 |
| Slade, S | 1 |
| Allenby, C | 1 |
| Kutlu, MG | 1 |
| Levin, ED | 1 |
| Foote, M | 1 |
| Qiao, H | 1 |
| Graham, K | 1 |
| Wu, Y | 1 |
| Zhou, Y | 1 |
| Stasi, MA | 3 |
| Minetti, P | 1 |
| Lombardo, K | 1 |
| Riccioni, T | 1 |
| Caprioli, A | 1 |
| Vertechy, M | 1 |
| Di Serio, S | 1 |
| Pace, S | 1 |
| Borsini, F | 3 |
| Mustafa, G | 1 |
| Ahuja, A | 1 |
| Al Rohaimi, AH | 1 |
| Muslim, S | 1 |
| Hassan, AA | 1 |
| Belluzzi, JD | 1 |
| Frau, R | 2 |
| Abbiati, F | 1 |
| Bini, V | 1 |
| Casti, A | 1 |
| Caruso, D | 1 |
| Devoto, P | 1 |
| Iderberg, H | 1 |
| McCreary, AC | 1 |
| Varney, MA | 1 |
| Kleven, MS | 3 |
| Koek, W | 3 |
| Bardin, L | 1 |
| Depoortère, R | 2 |
| Cenci, MA | 2 |
| Newman-Tancredi, A | 2 |
| Wei, Y | 1 |
| Wang, X | 1 |
| Yu, Z | 1 |
| Zhou, W | 1 |
| Qin, F | 1 |
| Wang, C | 1 |
| Hou, L | 1 |
| Xavier, G | 1 |
| Spindola, LN | 1 |
| Moretti, PN | 1 |
| Martins, DF | 1 |
| Emer, AA | 1 |
| Batisti, AP | 1 |
| Donatello, N | 1 |
| Carlesso, MG | 1 |
| Mazzardo-Martins, L | 1 |
| Venzke, D | 1 |
| Micke, GA | 1 |
| Pizzolatti, MG | 1 |
| Piovezan, AP | 1 |
| dos Santos, AR | 1 |
| Lv, MH | 3 |
| Soares, JC | 3 |
| Kosmowska, B | 1 |
| Wardas, J | 3 |
| Głowacka, U | 1 |
| Ananthan, S | 1 |
| Ossowska, K | 5 |
| Antonio, CB | 1 |
| Betti, AH | 1 |
| Herzfeldt, V | 1 |
| Barreiro, EJ | 1 |
| Fraga, CA | 1 |
| Rates, SM | 1 |
| Maurice, N | 1 |
| Deltheil, T | 1 |
| Degos, B | 1 |
| Mourre, C | 1 |
| Amalric, M | 5 |
| Stepan, J | 1 |
| Hladky, F | 1 |
| Uribe, A | 1 |
| Holsboer, F | 1 |
| Schmidt, MV | 1 |
| Eder, M | 1 |
| Andrzejewski, K | 1 |
| Budzińska, K | 1 |
| Zaremba, M | 1 |
| Kaczyńska, K | 1 |
| Volk, DW | 1 |
| Edelson, JR | 1 |
| Lewis, DA | 1 |
| Hudson, MR | 1 |
| Rind, G | 1 |
| O'Brien, TJ | 1 |
| Jones, NC | 1 |
| Madularu, D | 1 |
| Kulkarni, P | 1 |
| Yee, JR | 1 |
| Kenkel, WM | 1 |
| Shams, WM | 1 |
| Ferris, CF | 1 |
| Brake, WG | 1 |
| Oliveira, LR | 1 |
| Dias, FRC | 1 |
| Santos, BG | 1 |
| Silva, JLL | 1 |
| Carey, RJ | 1 |
| Carrera, MP | 1 |
| Yan, SX | 1 |
| Wu, JQ | 1 |
| Uys, M | 1 |
| Shahid, M | 1 |
| Sallinen, J | 1 |
| Dreyer, W | 1 |
| Cockeran, M | 1 |
| Harvey, BH | 3 |
| Jones, CK | 3 |
| Lin, X | 1 |
| Bubser, M | 3 |
| Thompson Gray, A | 1 |
| Engers, DW | 2 |
| Daniels, JS | 2 |
| Hopkins, CR | 2 |
| Javitch, JA | 1 |
| Bordia, T | 1 |
| Zhang, D | 1 |
| Perez, XA | 1 |
| Quik, M | 1 |
| Jensen, RJ | 1 |
| Rajput, SK | 1 |
| Meena, CL | 1 |
| Pant, AB | 1 |
| Jain, R | 1 |
| Sharma, SS | 1 |
| Kronbauer, M | 1 |
| Metz, VG | 1 |
| Roversi, K | 1 |
| Dias, VT | 2 |
| de David Antoniazzi, CT | 1 |
| da Silva Barcelos, RC | 1 |
| Burger, ME | 6 |
| Zhou, D | 1 |
| Yang, F | 1 |
| Giné, E | 1 |
| Echeverry-Alzate, V | 1 |
| Lopez-Moreno, JA | 1 |
| Rodriguez de Fonseca, F | 1 |
| Perez-Castillo, A | 1 |
| Santos, A | 1 |
| Funk, AJ | 1 |
| Mielnik, CA | 1 |
| Koene, R | 1 |
| Newburn, E | 1 |
| Ramsey, AJ | 1 |
| Lipska, BK | 4 |
| McCullumsmith, RE | 2 |
| Yasmin, F | 1 |
| Ohno, Y | 2 |
| Shimizu, S | 2 |
| Imaki, J | 2 |
| Ishihara, S | 2 |
| Sofue, N | 2 |
| Sasa, M | 3 |
| Kawai, Y | 2 |
| Varty, GB | 1 |
| Pond, AJ | 1 |
| Grzelak, ME | 1 |
| Parker, EM | 1 |
| Amato, D | 1 |
| Nencini, P | 4 |
| Haleem, MA | 1 |
| Lopez, S | 3 |
| Turle-Lorenzo, N | 2 |
| Johnston, TH | 1 |
| Brotchie, JM | 1 |
| Schann, S | 1 |
| Neuville, P | 1 |
| Dhein, S | 1 |
| Perlitz, F | 1 |
| Mohr, FW | 1 |
| Barak, S | 1 |
| Weiner, I | 8 |
| Stone, EA | 1 |
| Lin, Y | 2 |
| Quartermain, D | 2 |
| Palmer, AA | 1 |
| Brown, AS | 1 |
| Keegan, D | 1 |
| Siska, LD | 1 |
| Susser, E | 1 |
| Rotrosen, J | 1 |
| Butler, PD | 1 |
| Meyer, U | 1 |
| Spoerri, E | 1 |
| Yee, BK | 3 |
| Schwarz, MJ | 1 |
| Feldon, J | 5 |
| Azam, F | 1 |
| Barodia, SK | 2 |
| Anwer, T | 1 |
| Alam, MM | 1 |
| Batool, F | 1 |
| Zhang, X | 1 |
| Tellew, JE | 1 |
| Luo, Z | 1 |
| Moorjani, M | 1 |
| Lin, E | 1 |
| Lanier, MC | 1 |
| Williams, JP | 1 |
| Saunders, J | 1 |
| Lechner, SM | 1 |
| Markison, S | 1 |
| Joswig, T | 1 |
| Petroski, R | 1 |
| Piercey, J | 1 |
| Kargo, W | 1 |
| Malany, S | 1 |
| Santos, M | 1 |
| Gross, RS | 1 |
| Wen, J | 1 |
| Jalali, K | 1 |
| O'Brien, Z | 1 |
| Stotz, CE | 1 |
| Crespo, MI | 1 |
| Díaz, JL | 1 |
| Slee, DH | 1 |
| Ehrlichman, RS | 1 |
| Gandal, MJ | 1 |
| Maxwell, CR | 3 |
| Lazarewicz, MT | 1 |
| Finkel, LH | 1 |
| Contreras, D | 1 |
| Turetsky, BI | 1 |
| Siegel, SJ | 3 |
| Kelly, MP | 2 |
| Stein, JM | 1 |
| Vecsey, CG | 1 |
| Favilla, C | 1 |
| Yang, X | 1 |
| Bizily, SF | 1 |
| Esposito, MF | 1 |
| Wand, G | 1 |
| Kanes, SJ | 3 |
| Abel, T | 2 |
| Sun, T | 1 |
| Hu, G | 3 |
| Li, M | 3 |
| Luthra, PM | 1 |
| Raghubir, R | 1 |
| Arad, M | 2 |
| Seeman, P | 1 |
| Entrena, JM | 1 |
| Cobos, EJ | 1 |
| Nieto, FR | 1 |
| Cendán, CM | 1 |
| Baeyens, JM | 1 |
| Del Pozo, E | 1 |
| Ciucci, MR | 1 |
| Ahrens, AM | 1 |
| Ma, ST | 1 |
| Kane, JR | 1 |
| Windham, EB | 1 |
| Woodlee, MT | 1 |
| Schallert, T | 2 |
| Ghose, S | 1 |
| Gleason, KA | 1 |
| Potts, BW | 1 |
| Lewis-Amezcua, K | 1 |
| Tamminga, CA | 6 |
| Beurrier, C | 1 |
| Révy, D | 1 |
| Selvam, C | 1 |
| Goudet, C | 1 |
| Lhérondel, M | 1 |
| Kerkerian-LeGoff, L | 1 |
| Acher, F | 1 |
| Pin, JP | 1 |
| Stevenson, GW | 2 |
| Cormier, J | 1 |
| Mercer, H | 1 |
| Adams, C | 1 |
| Dunbar, C | 1 |
| Negus, SS | 2 |
| Bilsky, EJ | 2 |
| van der Staay, FJ | 1 |
| Pouzet, B | 4 |
| Mahieu, M | 1 |
| Nordquist, RE | 1 |
| Schuurman, T | 1 |
| Barcelos, RC | 3 |
| Benvegnú, DM | 3 |
| Boufleur, N | 3 |
| Reckziegel, P | 3 |
| Müller, LG | 1 |
| Pase, C | 1 |
| Emanuelli, T | 1 |
| Brown, AR | 1 |
| Hu, B | 1 |
| Antle, MC | 1 |
| Teskey, GC | 1 |
| Uyanik, A | 1 |
| Unal, D | 1 |
| Halici, Z | 1 |
| Cetinkaya, R | 1 |
| Altunkaynak, BZ | 1 |
| Keles, ON | 1 |
| Polat, B | 1 |
| Topal, A | 1 |
| Colak, S | 1 |
| Suleyman, H | 1 |
| Unal, B | 1 |
| Toua, C | 1 |
| Brand, L | 1 |
| Möller, M | 1 |
| Emsley, RA | 1 |
| Yang, ZJ | 1 |
| Carter, EL | 1 |
| Torbey, MT | 1 |
| Martin, LJ | 1 |
| Koehler, RC | 2 |
| Greco, B | 1 |
| van der Putten, H | 1 |
| Flor, PJ | 1 |
| Paterson, NE | 1 |
| Hanania, T | 1 |
| Mabrouk, OS | 1 |
| Marti, M | 2 |
| Morari, M | 2 |
| Lipina, T | 1 |
| Roder, J | 1 |
| De Brito Gariepy, H | 1 |
| Carayon, P | 1 |
| Ferrari, B | 1 |
| Couture, R | 1 |
| López-Téllez, JF | 1 |
| López-Aranda, MF | 1 |
| Navarro-Lobato, I | 1 |
| Masmudi-Martín, M | 1 |
| Montañez, EM | 1 |
| Calvo, EB | 1 |
| Khan, ZU | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Zhang, XR | 1 |
| Zhang, ZJ | 2 |
| Jenkins, TA | 1 |
| Cheng, WR | 1 |
| Reynolds, GP | 1 |
| Keilhoff, G | 1 |
| Grecksch, G | 1 |
| Becker, A | 1 |
| Milella, MS | 2 |
| Passarelli, F | 1 |
| De Carolis, L | 3 |
| Schepisi, C | 2 |
| Nativio, P | 1 |
| Scaccianoce, S | 1 |
| Sarubbo, S | 1 |
| Latini, F | 1 |
| Cavallo, M | 1 |
| Eleopra, R | 1 |
| Biguzzi, S | 1 |
| Lettieri, C | 1 |
| Conti, C | 1 |
| Quatrale, R | 1 |
| Sensi, M | 1 |
| Candeletti, S | 1 |
| Romualdi, P | 1 |
| Krzyzosiak, A | 1 |
| Szyszka-Niagolov, M | 1 |
| Wietrzych, M | 1 |
| Gobaille, S | 1 |
| Muramatsu, S | 1 |
| Krezel, W | 1 |
| Serlupi-Crescenzi, O | 1 |
| Creed, M | 1 |
| Hamani, C | 2 |
| Nobrega, JN | 3 |
| Negrete-Díaz, JV | 1 |
| Baltazar-Gaytán, E | 1 |
| Bringas, ME | 1 |
| Vazquez-Roque, RA | 1 |
| Newton, S | 1 |
| Aguilar-Alonso, P | 1 |
| León-Chávez, BA | 1 |
| Flores, G | 1 |
| Bubenikova-Valesova, V | 1 |
| Svoboda, J | 1 |
| Horacek, J | 1 |
| Sumiyoshi, T | 1 |
| Chatterjee, M | 1 |
| Ganguly, S | 1 |
| Srivastava, M | 1 |
| Palit, G | 1 |
| Wadenberg, ML | 2 |
| Fjällström, AK | 1 |
| Federley, M | 1 |
| Persson, P | 1 |
| Stenqvist, P | 1 |
| Goetghebeur, PJ | 1 |
| Lerdrup, L | 1 |
| Sylvest, A | 1 |
| Dias, R | 1 |
| Abekawa, T | 1 |
| Ito, K | 1 |
| Nakagawa, S | 1 |
| Nakato, Y | 1 |
| Koyama, T | 1 |
| Xue, Y | 1 |
| Chen, L | 1 |
| Carli, M | 1 |
| Calcagno, E | 1 |
| Mainolfi, P | 1 |
| Mainini, E | 1 |
| Invernizzi, RW | 1 |
| Bishnoi, M | 6 |
| Chopra, K | 5 |
| Rongzhu, L | 1 |
| Kulkarni, SK | 8 |
| Laplante, F | 1 |
| Lappi, DA | 1 |
| Sullivan, RM | 1 |
| Pase, CS | 2 |
| Ourique, AF | 1 |
| Beck, RC | 1 |
| Trevizol, F | 1 |
| Segat, HJ | 1 |
| Dolci, GS | 1 |
| Il'ina, IV | 1 |
| Morozova, EA | 1 |
| Korchagina, DV | 1 |
| Karpova, EV | 1 |
| Kaminer, J | 1 |
| Powers, AS | 1 |
| Horn, KG | 1 |
| Hui, C | 1 |
| Evinger, C | 1 |
| Greenbaum, L | 1 |
| Lifschytz, T | 1 |
| Zozulinsky, P | 1 |
| Broner, EC | 1 |
| Slonimsky, A | 1 |
| Kohn, Y | 1 |
| Lerer, B | 1 |
| Savio, LE | 1 |
| Vuaden, FC | 1 |
| Piato, AL | 1 |
| Bonan, CD | 1 |
| Wyse, AT | 1 |
| Dobryakova, YV | 1 |
| Dubynin, VA | 1 |
| Luijtelaar, GV | 1 |
| Thompson, AD | 1 |
| Bridges, TM | 1 |
| Morrison, RD | 1 |
| Jadhav, S | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Patil, R | 1 |
| Hiray, Y | 1 |
| Shinde, S | 1 |
| Langade, P | 1 |
| Boparai, RK | 1 |
| Bilge, U | 1 |
| Erol, K | 1 |
| Banasikowski, TJ | 1 |
| Beninger, RJ | 1 |
| Wilmsdorff, MV | 1 |
| Blaich, C | 1 |
| Zink, M | 3 |
| Treutlein, J | 1 |
| Bauer, M | 1 |
| Schulze, T | 1 |
| Schneider-Axmann, T | 1 |
| Gruber, O | 1 |
| Rietschel, M | 1 |
| Schmitt, A | 3 |
| Falkai, P | 2 |
| Schmidt-Hansen, M | 1 |
| Le Pelley, M | 1 |
| Kazmi, I | 1 |
| Afzal, M | 1 |
| Rahman, M | 1 |
| Saleem, S | 1 |
| Ashraf, MS | 1 |
| Khusroo, MJ | 1 |
| Nazeer, K | 1 |
| Ahmed, S | 1 |
| Mujeeb, M | 1 |
| Ahmed, Z | 1 |
| Bennouar, KE | 1 |
| Uberti, MA | 1 |
| Bacolod, MD | 1 |
| Jimenez, HN | 1 |
| Cajina, M | 1 |
| Genius, J | 2 |
| Benninghoff, J | 1 |
| Reuter, N | 1 |
| Braun, I | 2 |
| Giegling, I | 1 |
| Hartmann, A | 1 |
| Möller, HJ | 2 |
| Rujescu, D | 2 |
| de Vargas Pinheiro, F | 1 |
| da Silva Sant'Anna, G | 1 |
| Machado, P | 1 |
| Dombrowski, PA | 1 |
| da Cunha, C | 1 |
| de Almeida Cabrini, D | 1 |
| Pinto Martins, MA | 1 |
| Gauze Bonacorso, H | 1 |
| Zanatta, N | 1 |
| Antonello Rubin, M | 1 |
| Ionov, ID | 1 |
| Severtsev, NN | 1 |
| Johnson, KA | 1 |
| Tantawy, MN | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Joshi, M | 1 |
| Akhtar, M | 1 |
| Najmi, AK | 1 |
| Khuroo, AH | 1 |
| Goswami, D | 1 |
| Chindo, BA | 1 |
| Adzu, B | 1 |
| Yahaya, TA | 1 |
| Gamaniel, KS | 1 |
| Ozdemir, H | 1 |
| Ertugrul, A | 1 |
| Basar, K | 1 |
| Saka, E | 1 |
| Revel, FG | 1 |
| Moreau, JL | 2 |
| Mory, R | 1 |
| Bradaia, A | 1 |
| Buchy, D | 1 |
| Metzler, V | 1 |
| Chaboz, S | 1 |
| Groebke Zbinden, K | 1 |
| Galley, G | 1 |
| Norcross, RD | 1 |
| Tuerck, D | 1 |
| Bruns, A | 1 |
| Morairty, SR | 1 |
| Kilduff, TS | 1 |
| Wallace, TL | 1 |
| Risterucci, C | 1 |
| Wettstein, JG | 1 |
| Hoener, MC | 1 |
| Ellis, LD | 1 |
| Soanes, KH | 1 |
| Hannaway, KE | 1 |
| Adelekun, AE | 1 |
| Jayathilake, K | 1 |
| Rizig, MA | 1 |
| McQuillin, A | 1 |
| Ng, A | 1 |
| Robinson, M | 1 |
| Harrison, A | 1 |
| Zvelebil, M | 1 |
| Hunt, SP | 1 |
| Gurling, HM | 1 |
| Creed, MC | 1 |
| Bridgman, A | 1 |
| Fletcher, PJ | 2 |
| Wang, D | 1 |
| Wong, HK | 1 |
| Zhang, L | 1 |
| McAlonan, GM | 1 |
| Wang, XM | 1 |
| Sze, SC | 1 |
| Feng, YB | 1 |
| Dygai, AM | 2 |
| Skurikhin, EG | 2 |
| Andreeva, TV | 1 |
| Pershina, OV | 1 |
| Ermolaeva, LA | 1 |
| Khmelevskaya, ES | 1 |
| Krupin, VA | 1 |
| Reztsova, AM | 1 |
| Stepanova, IE | 1 |
| Gershteĭn, LM | 1 |
| Tatarintseva, IM | 1 |
| Sergutina, AV | 1 |
| Rakhmanova, VI | 1 |
| Goldstein, N | 1 |
| Goldstein, R | 1 |
| Terterov, D | 1 |
| Kamensky, AA | 1 |
| Kovalev, GI | 1 |
| Zolotarev, YA | 1 |
| Avakyan, GN | 1 |
| Terterov, S | 1 |
| Moreno, JL | 1 |
| Holloway, T | 1 |
| Umali, A | 1 |
| Rayannavar, V | 1 |
| Sealfon, SC | 1 |
| González-Maeso, J | 1 |
| Taylor, GT | 1 |
| Smith, SE | 1 |
| Kirchhoff, BA | 1 |
| Sparkman, NL | 1 |
| Sekiguchi, K | 1 |
| Kanno, H | 1 |
| Yamaguchi, T | 1 |
| Ikarashi, Y | 1 |
| Kase, Y | 1 |
| Schmidt, TT | 1 |
| Rea, E | 1 |
| Shababi-Klein, J | 1 |
| Panagis, G | 1 |
| Winter, C | 1 |
| Su, CJ | 1 |
| Xu, XQ | 1 |
| Fan, Y | 1 |
| Du, RH | 1 |
| Cheng, JT | 2 |
| Li, JS | 1 |
| Baptista, PP | 1 |
| de Senna, PN | 1 |
| Paim, MF | 1 |
| Saur, L | 1 |
| Blank, M | 2 |
| do Nascimento, P | 1 |
| Ilha, J | 1 |
| Vianna, MR | 1 |
| Mestriner, RG | 1 |
| Achaval, M | 1 |
| Xavier, LL | 1 |
| Kreiss, DS | 1 |
| Coffman, CF | 1 |
| Fiacco, NR | 1 |
| Granger, JC | 1 |
| Helton, BM | 1 |
| Jackson, JC | 1 |
| Kim, LV | 1 |
| Mistry, RS | 1 |
| Mizer, TM | 1 |
| Palmer, LV | 1 |
| Vacca, JA | 1 |
| Winkler, SS | 1 |
| Zimmer, BA | 1 |
| Paine, TA | 1 |
| Asinof, SK | 1 |
| Diehl, GW | 1 |
| Frackman, A | 1 |
| Leffler, J | 1 |
| Shan, D | 1 |
| Lucas, EK | 1 |
| Drummond, JB | 1 |
| Haroutunian, V | 1 |
| Meador-Woodruff, JH | 1 |
| Goto, Y | 1 |
| O'Donnell, P | 1 |
| Simosky, JK | 1 |
| Stevens, KE | 2 |
| Adler, LE | 1 |
| Freedman, R | 1 |
| Bhattachary, SK | 1 |
| Bhattacharya, D | 2 |
| Muruganandam, AV | 1 |
| Klein, A | 1 |
| Schmidt, WJ | 3 |
| Gaisler-Salomon, I | 1 |
| Sharma, S | 1 |
| Paladino, P | 1 |
| Gabriele, J | 1 |
| Saeedi, H | 1 |
| Henry, P | 2 |
| Chang, M | 1 |
| Mishra, RK | 2 |
| Johnson, RL | 1 |
| Carvalho, RC | 1 |
| Silva, RH | 1 |
| Barbosa, PN | 1 |
| Kehl, LJ | 1 |
| Hamamoto, DT | 1 |
| Wacnik, PW | 1 |
| Croft, DL | 1 |
| Norsted, BD | 1 |
| Wilcox, GL | 1 |
| Simone, DA | 1 |
| Mow, T | 1 |
| Kreilgaard, M | 1 |
| Velschow, S | 1 |
| Rukoyatkina, NI | 1 |
| Gorbunova, LV | 1 |
| Gmiro, VE | 1 |
| Lukomskaya, NY | 1 |
| Srinivasan, J | 1 |
| Sugiyama, A | 1 |
| Linn, GS | 1 |
| Negi, SS | 1 |
| Gerum, SV | 1 |
| Javitt, DC | 2 |
| Ukai, M | 1 |
| Mitsunaga, H | 1 |
| Zuckerman, L | 2 |
| Rehavi, M | 1 |
| Nachman, R | 1 |
| Nel, A | 1 |
| Naidu, PS | 2 |
| Singh, A | 2 |
| Andreassen, OA | 4 |
| Ferrante, RJ | 1 |
| Aamo, TO | 1 |
| Beal, MF | 1 |
| Jørgensen, HA | 4 |
| Pietraszek, M | 2 |
| Wolfarth, S | 5 |
| Meredith, GE | 2 |
| Switzer, RC | 1 |
| Napier, TC | 1 |
| El Yacoubi, M | 2 |
| Costentin, J | 2 |
| Vaugeois, JM | 2 |
| Wisniecki, A | 1 |
| Betz, A | 1 |
| Dobson, DR | 1 |
| O'Neill, MF | 1 |
| O'Neill, MJ | 1 |
| May, B | 2 |
| Müller, B | 2 |
| Braus, DF | 2 |
| Henn, FA | 2 |
| Shintani, N | 1 |
| Tanaka, K | 1 |
| Baba, A | 1 |
| Marchese, G | 1 |
| Bartholini, F | 1 |
| Casu, MA | 1 |
| Ruiu, S | 1 |
| Casti, P | 1 |
| Congeddu, E | 1 |
| Tambaro, S | 1 |
| Pani, L | 2 |
| Feifel, D | 2 |
| Melendez, G | 2 |
| Shilling, PD | 2 |
| Hamann, M | 1 |
| Meisler, MH | 1 |
| Richter, A | 2 |
| Shoham, S | 1 |
| Mazeh, H | 1 |
| Heresco-Levy, U | 1 |
| Ando, N | 1 |
| Morimoto, K | 1 |
| Watanabe, T | 1 |
| Ninomiya, T | 1 |
| Suwaki, H | 1 |
| Hussain, N | 1 |
| Flumerfelt, BA | 1 |
| Rajakumar, N | 1 |
| Demirakca, T | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Mutoh, S | 1 |
| Miglio, G | 1 |
| Varsaldi, F | 1 |
| Francioli, E | 1 |
| Battaglia, A | 1 |
| Canonico, PL | 2 |
| Lombardi, G | 1 |
| Tort, AB | 1 |
| Dall'Igna, OP | 1 |
| de Oliveira, RV | 1 |
| Mantese, CE | 1 |
| Fett, P | 1 |
| Gomes, MW | 1 |
| Schuh, J | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Ethier, I | 1 |
| Kagechika, H | 1 |
| Shudo, K | 1 |
| Rouillard, C | 1 |
| Rogoza, RM | 1 |
| Fairfax, DF | 1 |
| N-Marandi, S | 1 |
| Khan, RF | 1 |
| Gupta, SK | 1 |
| Lebsanft, HB | 1 |
| Kohles, T | 1 |
| Kovar, KA | 1 |
| Wylot, M | 1 |
| Laszczyńska, M | 1 |
| Słuczanowska-Glabowska, S | 1 |
| Piasecka, M | 1 |
| Fachineto, R | 1 |
| Alves, A | 1 |
| Callegari, L | 1 |
| Rocha, JB | 2 |
| Turrone, P | 1 |
| Remington, G | 2 |
| Kapur, S | 4 |
| Sawada, K | 1 |
| Barr, AM | 1 |
| Nakamura, M | 1 |
| Arima, K | 1 |
| Young, CE | 1 |
| Dwork, AJ | 1 |
| Phillips, AG | 1 |
| Honer, WG | 1 |
| Tenn, CC | 1 |
| Lazzarini, M | 1 |
| Salum, C | 1 |
| Del Bel, EA | 1 |
| Terranova, JP | 1 |
| Chabot, C | 1 |
| Barnouin, MC | 1 |
| Perrault, G | 1 |
| Griebel, G | 1 |
| Scatton, B | 1 |
| Hu, LF | 1 |
| Yang, Y | 1 |
| Ding, JH | 1 |
| Cosi, C | 1 |
| Waget, A | 1 |
| Rollet, K | 1 |
| Tesori, V | 1 |
| Schiller, D | 1 |
| Wong, AH | 1 |
| Likhodi, O | 1 |
| Boffa, E | 1 |
| Weinberger, DR | 4 |
| Kennedy, JL | 1 |
| Van Tol, HH | 1 |
| Majumdar, S | 1 |
| Trief, DF | 1 |
| Lerman, C | 1 |
| Gur, RE | 1 |
| Liang, Y | 2 |
| Pilc, A | 2 |
| Parr-Brownlie, LC | 1 |
| Hyland, BI | 1 |
| Schleimer, SB | 1 |
| Johnston, GA | 1 |
| Henderson, JM | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 2 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Matsushita, M | 1 |
| Egashira, N | 1 |
| Harada, S | 1 |
| Okuno, R | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| Rosengarten, H | 1 |
| Bartoszyk, GD | 1 |
| Keist, R | 1 |
| von Boehmer, L | 1 |
| Studer, R | 1 |
| Benke, D | 1 |
| Hagenbuch, N | 1 |
| Dong, Y | 1 |
| Malenka, RC | 1 |
| Fritschy, JM | 1 |
| Bluethmann, H | 1 |
| Möhler, H | 1 |
| Rudolph, U | 1 |
| Pires, JG | 1 |
| Bonikovski, V | 1 |
| Futuro-Neto, HA | 1 |
| Leveleki, C | 1 |
| Sziray, N | 1 |
| Levay, G | 1 |
| Barsvári, B | 1 |
| Soproni, K | 1 |
| Mikics, E | 1 |
| Haller, J | 1 |
| Pillai, A | 1 |
| Parikh, V | 1 |
| Terry, AV | 1 |
| Mahadik, SP | 1 |
| Dekundy, A | 1 |
| Schaefer, D | 1 |
| Danysz, W | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Kesby, JP | 1 |
| Burne, TH | 1 |
| McGrath, JJ | 1 |
| Eyles, DW | 1 |
| Smith, AJ | 1 |
| Becker, S | 1 |
| Wagner, C | 1 |
| Perottoni, J | 1 |
| Pereira, RP | 1 |
| Zeni, G | 1 |
| Minet-Ringuet, J | 1 |
| Even, PC | 1 |
| Lacroix, M | 1 |
| Tomé, D | 1 |
| de Beaurepaire, R | 1 |
| El-Mallakh, RS | 1 |
| Decker, S | 1 |
| Morris, M | 1 |
| Huff, MO | 1 |
| El-Masri, MA | 1 |
| Levy, RS | 1 |
| Kim, HS | 1 |
| Song, M | 1 |
| Yumkham, S | 1 |
| Choi, JH | 1 |
| Lee, T | 1 |
| Kwon, J | 1 |
| Lee, SJ | 1 |
| Kim, JI | 1 |
| Lee, KW | 1 |
| Han, PL | 1 |
| Shin, SW | 1 |
| Baik, JH | 1 |
| Kim, YS | 1 |
| Ryu, SH | 1 |
| Suh, PG | 1 |
| Paulson, L | 1 |
| Martin, P | 1 |
| Ljung, E | 1 |
| Blennow, K | 1 |
| Davidsson, P | 1 |
| Turgeon, SM | 1 |
| Hulick, VC | 1 |
| Katzav, A | 1 |
| Solodeev, I | 1 |
| Brodsky, O | 1 |
| Chapman, J | 1 |
| Pick, CG | 1 |
| Zhang, W | 2 |
| Reichlin, M | 1 |
| Shoenfeld, Y | 1 |
| Morice, E | 1 |
| Billard, JM | 1 |
| Denis, C | 1 |
| Mathieu, F | 1 |
| Betancur, C | 1 |
| Epelbaum, J | 1 |
| Giros, B | 1 |
| Nosten-Bertrand, M | 1 |
| Kato, T | 1 |
| Monji, A | 1 |
| Hashioka, S | 1 |
| Kanba, S | 1 |
| Didriksen, M | 1 |
| Skarsfeldt, T | 1 |
| Arnt, J | 1 |
| Machado, RA | 1 |
| Constantino, L | 1 |
| Martins, MR | 1 |
| de Albuquerque, IM | 1 |
| Menna-Barreto, S | 1 |
| Streck, E | 1 |
| Dal-Pizzol, F | 1 |
| Amitai, N | 1 |
| Semenova, S | 1 |
| Markou, A | 1 |
| Ikram, H | 1 |
| Priebe, K | 1 |
| Grunze, H | 1 |
| Bender, A | 1 |
| Orrù, M | 1 |
| Piras, AP | 1 |
| Fà, M | 1 |
| Tuveri, A | 1 |
| Puligheddu, M | 1 |
| Gessa, GL | 4 |
| Castelli, MP | 1 |
| Mereu, G | 2 |
| Marrosu, F | 1 |
| Mongeau, R | 1 |
| Marcello, S | 1 |
| Andersen, JS | 1 |
| Koh, HY | 1 |
| Kim, D | 1 |
| Lee, J | 1 |
| Lee, S | 1 |
| Shin, HS | 1 |
| Schlenker, EH | 1 |
| Charvin, D | 1 |
| Roze, E | 1 |
| Perrin, V | 1 |
| Deyts, C | 1 |
| Betuing, S | 1 |
| Pagès, C | 1 |
| Régulier, E | 1 |
| Luthi-Carter, R | 1 |
| Brouillet, E | 1 |
| Déglon, N | 1 |
| Caboche, J | 1 |
| Duarte, FS | 1 |
| Lach, G | 1 |
| Martins, PR | 1 |
| Romeiro, GA | 1 |
| de Lima, TC | 1 |
| Yao, Y | 1 |
| Ma, HW | 1 |
| Lu, Y | 1 |
| Dai, XM | 1 |
| Snigdha, S | 1 |
| Neill, JC | 1 |
| McLeod, MC | 1 |
| Sundram, S | 1 |
| Dean, B | 1 |
| Martinez, V | 1 |
| Sarter, M | 1 |
| Verma, V | 1 |
| Tan, CH | 1 |
| Ong, WY | 1 |
| Grigoryan, GA | 1 |
| Jones, CA | 1 |
| Stolzberg, D | 1 |
| Salvi, R | 1 |
| Gross, KW | 1 |
| Ratty, AK | 1 |
| Khan, A | 1 |
| Perveen, T | 1 |
| Haider, S | 1 |
| Abdul Haleem, M | 1 |
| Rygula, R | 1 |
| Abumaria, N | 1 |
| Havemann-Reinecke, U | 1 |
| Rüther, E | 1 |
| Hiemke, C | 1 |
| Zernig, G | 1 |
| Fuchs, E | 1 |
| Flügge, G | 1 |
| Reavill, C | 1 |
| Jenner, P | 2 |
| Marsden, CD | 3 |
| Glassman, RB | 1 |
| Glassman, HN | 1 |
| Porsolt, RD | 1 |
| Jalfre, M | 1 |
| Klawans, HL | 7 |
| Goetz, CG | 4 |
| Carvey, P | 4 |
| Rastogi, SK | 2 |
| Rastogi, RB | 2 |
| Singhal, RL | 2 |
| Lapierre, YD | 2 |
| Andreas, K | 1 |
| Fischer, HD | 1 |
| Schmidt, J | 1 |
| Zigmond, MJ | 1 |
| Stricker, EM | 1 |
| Koller, W | 1 |
| Curtin, J | 1 |
| Fields, J | 1 |
| Herrera-Marschitz, M | 1 |
| Strömberg, I | 1 |
| Olsson, D | 1 |
| Ungerstedt, U | 1 |
| Olson, L | 1 |
| Lorden, JF | 1 |
| McKeon, TW | 1 |
| Baker, HJ | 1 |
| Cox, N | 1 |
| Walkley, SU | 1 |
| Avrutskiĭ, GIa | 1 |
| Allikmets, LKh | 1 |
| Neduva, AA | 1 |
| Zharkovskiĭ, AM | 1 |
| Beliakov, AV | 1 |
| Krous, HF | 1 |
| Catron, AC | 1 |
| Farber, JP | 1 |
| Yonekawa, M | 1 |
| Kanaya, T | 1 |
| Sera, H | 1 |
| Sarai, K | 1 |
| Sundén-Kuronen, B | 1 |
| Pohto, P | 1 |
| Alanen, E | 1 |
| Morgenstern, R | 1 |
| Fink, H | 1 |
| Oelssner, W | 1 |
| Dubach, MF | 1 |
| Bowden, DM | 1 |
| Schechter, MD | 1 |
| Concannon, JT | 1 |
| Yarbrough, GG | 1 |
| Faison, EP | 1 |
| Antolik, EK | 1 |
| Bédard, PJ | 1 |
| Boucher, R | 2 |
| Larochelle, L | 2 |
| De Ryck, M | 1 |
| Teitelbaum, P | 2 |
| Diamond, BI | 3 |
| Reyes, MG | 1 |
| Borison, R | 1 |
| Scapagnini, U | 1 |
| Nicoletti, F | 1 |
| Patti, F | 1 |
| Fiore, L | 1 |
| Tigano, G | 1 |
| Clementi, G | 1 |
| Johnels, B | 1 |
| Steg, G | 1 |
| Gordon, JH | 1 |
| Katz, RJ | 1 |
| Sibel, M | 1 |
| Davidson, AB | 1 |
| van't Groenewout, JL | 1 |
| Stone, MR | 1 |
| Vo, VN | 1 |
| Truong, DD | 1 |
| Matsumoto, RR | 1 |
| Hyde, TM | 2 |
| Egan, MF | 2 |
| Wing, LL | 1 |
| Wyatt, RJ | 2 |
| Kleinman, JE | 1 |
| Rawlins, JN | 1 |
| Lilliu, V | 1 |
| Vargiu, P | 1 |
| Muntoni, AL | 1 |
| Diana, M | 2 |
| Culić, M | 1 |
| Saponjić, J | 1 |
| Janković, B | 1 |
| Rakić, L | 2 |
| Aliev, MN | 2 |
| Rzaev, RN | 1 |
| Mamedbeĭli, TN | 1 |
| Aliev, AN | 1 |
| Gao, XM | 3 |
| Kakigi, T | 2 |
| Friedman, MB | 1 |
| Hole, K | 1 |
| Kinoshita, H | 1 |
| Hasegawa, T | 1 |
| Katsumata, Y | 1 |
| Kameyama, T | 1 |
| Yamamoto, I | 1 |
| Nabeshima, T | 1 |
| LeDuc, PA | 1 |
| Mittleman, G | 1 |
| Woods, A | 1 |
| Smith, C | 1 |
| Szewczak, M | 1 |
| Dunn, RW | 1 |
| Cornfeldt, M | 1 |
| Corbett, R | 1 |
| Sakharov, D | 1 |
| Voronezhskaya, E | 1 |
| Nezlin, L | 1 |
| Thaker, GK | 1 |
| Moran, M | 1 |
| Xu, JH | 1 |
| Cao, H | 1 |
| Zheng, JH | 1 |
| Wishart, TB | 1 |
| Ijaz, S | 1 |
| Shuaib, A | 1 |
| Peacock, L | 1 |
| Gerlach, J | 2 |
| Bo, P | 2 |
| Soragna, D | 2 |
| Murelli, R | 1 |
| Albergati, A | 2 |
| Savoldi, F | 2 |
| Löscher, W | 1 |
| Arushanian, EB | 1 |
| Ovanesov, KB | 1 |
| Popov, AV | 1 |
| Popova, AP | 1 |
| Shchetinin, EV | 1 |
| Glenthøj, B | 1 |
| Mogensen, J | 1 |
| Laursen, H | 1 |
| Holm, S | 1 |
| Hemmingsen, R | 1 |
| Rudolf, G | 1 |
| Wioland, N | 1 |
| Jaskiw, GE | 1 |
| Swerdlow, NR | 1 |
| Geyer, MA | 1 |
| Marchioni, E | 1 |
| Candeloro, E | 1 |
| Lorenc-Koci, E | 3 |
| Takahashi, H | 2 |
| Kirsch, JR | 1 |
| London, ED | 1 |
| Traystman, RJ | 1 |
| Tanii, H | 1 |
| Taniguchi, N | 1 |
| Niigawa, H | 1 |
| Hosono, T | 1 |
| Ikura, Y | 1 |
| Sakamoto, S | 1 |
| Kudo, T | 1 |
| Nishimura, T | 1 |
| Takeda, M | 1 |
| Maurice, T | 1 |
| Privat, A | 1 |
| George, B | 1 |
| Krzaścik, P | 1 |
| Kostowski, W | 1 |
| Nagamoto, H | 1 |
| Johnson, RG | 1 |
| Adams, CE | 1 |
| Rose, GM | 1 |
| Sams-Dodd, F | 1 |
| Jentsch, JD | 1 |
| Taylor, JR | 1 |
| Roth, RH | 1 |
| Hashimoto, T | 1 |
| Ross, DE | 1 |
| Medoff, DR | 1 |
| Fowler, SC | 2 |
| Wang, G | 1 |
| Gómez, FM | 1 |
| Areso, MP | 1 |
| Giralt, MT | 1 |
| Sainz, B | 1 |
| García-Vallejo, P | 1 |
| Takeuchi, H | 1 |
| Ishigooka, J | 1 |
| Watanabe, S | 1 |
| Miura, S | 1 |
| Feinberg, I | 1 |
| Campbell, IG | 1 |
| Finsen, B | 1 |
| Ostergaard, K | 1 |
| Sørensen, JC | 1 |
| West, MJ | 1 |
| Prinssen, EP | 2 |
| Japha, K | 1 |
| Koch, M | 2 |
| Mohn, AR | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Koller, BH | 1 |
| Chinen, CC | 1 |
| Jongen-Rêlo, AL | 1 |
| Nöldner, M | 1 |
| Chatterjee, SS | 1 |
| Ikeda, H | 1 |
| Adachi, K | 1 |
| Hasegawa, M | 1 |
| Sato, M | 1 |
| Hirose, N | 1 |
| Koshikawa, N | 1 |
| Cools, AR | 2 |
| Casey, DE | 2 |
| Field, EF | 1 |
| Whishaw, IQ | 1 |
| Pellis, SM | 2 |
| Fendt, M | 1 |
| Schwienbacher, I | 1 |
| Joca, SR | 1 |
| Skalisz, LL | 1 |
| Beijamini, V | 1 |
| Vital, MA | 1 |
| Andreatini, R | 1 |
| Takahashi, S | 1 |
| Miwa, T | 1 |
| Horikomi, K | 1 |
| De Souza, IE | 1 |
| Tipper, G | 1 |
| Wong, ML | 1 |
| Colpaert, FC | 1 |
| Binder, EB | 1 |
| Kinkead, B | 1 |
| Owens, MJ | 1 |
| Kilts, CD | 1 |
| Nemeroff, CB | 1 |
| Yoshida, K | 1 |
| Sato, K | 1 |
| Higuchi, H | 1 |
| Shimizu, T | 1 |
| Bilic, I | 1 |
| Zoricic, I | 1 |
| Anic, T | 1 |
| Separovic, J | 1 |
| Stancic-Rokotov, D | 1 |
| Mikus, D | 1 |
| Buljat, G | 1 |
| Ivankovic, D | 1 |
| Aralica, G | 1 |
| Prkacin, I | 1 |
| Perovic, D | 1 |
| Mise, S | 1 |
| Rotkvic, I | 1 |
| Petek, M | 1 |
| Rucman, R | 1 |
| Guan, HJ | 1 |
| Dai, J | 1 |
| Zhu, XZ | 1 |
| Suslov, NI | 1 |
| Provalova, NV | 1 |
| Zyuz'kov, GN | 1 |
| Gol'dberg, ED | 1 |
| Crocker, AD | 1 |
| Hemsley, KM | 1 |
| Vukosavic, S | 1 |
| Ruzdijic, S | 1 |
| Veskov, R | 1 |
| Kanazir, S | 1 |
| Ellenbroek, BA | 1 |
| Liégeois, JF | 1 |
| Bruhwyler, J | 1 |
| Nakamura, K | 1 |
| Kurasawa, M | 1 |
| Turenne, SD | 1 |
| Seeman, M | 1 |
| Ross, BM | 1 |
| Midzianovskaia, IS | 1 |
| Kuznetsova, GD | 1 |
| Coenen, AM | 1 |
| Spiridonov, AM | 1 |
| van Luijtelaar, EL | 1 |
| Chang, CK | 1 |
| Chien, CH | 1 |
| Chou, HL | 1 |
| Lin, MT | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Bertorelli, R | 1 |
| Ongini, E | 1 |
| MacGibbon, GA | 1 |
| Hamilton, LC | 1 |
| Crocker, SF | 1 |
| Costain, WJ | 1 |
| Murphy, KM | 1 |
| Robertson, HA | 1 |
| Denovan-Wright, EM | 1 |
| Bhattacharya, SK | 1 |
| Sairam, K | 1 |
| Ghosal, S | 1 |
| Le Pen, G | 1 |
| Andersson, C | 1 |
| Hamer, RM | 1 |
| Lawler, CP | 1 |
| Mailman, RB | 1 |
| Lieberman, JA | 1 |
| Val'dman, AV | 1 |
| Kozlovskaia, MM | 1 |
| Dill, RE | 1 |
| Dorris, RL | 1 |
| Phillips-Thonnard, I | 1 |
| Sambrook, MA | 1 |
| Crossman, AR | 1 |
| Slater, P | 1 |
| Stoff, DM | 1 |
| Moja, EA | 1 |
| Gillin, JC | 1 |
| Meldrum, BS | 1 |
| Anlezark, GM | 1 |
| Weiss, B | 1 |
| Santelli, S | 1 |
| Nausieda, PA | 2 |
| Koller, WC | 1 |
| Weiner, WJ | 2 |
| Borison, RL | 1 |
| Havdala, HS | 1 |
| Davis, KL | 1 |
| Hollister, LE | 1 |
| Vento, AL | 1 |
| Simonton, S | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Hitri, A | 1 |
| Battista, AF | 1 |
| Goldstein, M | 1 |
| Miyamoto, T | 1 |
| Matsumoto, Y | 1 |
| Gunne, LM | 2 |
| Bárány, S | 1 |
| Sayers, AC | 1 |
| Bürki, HR | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Collu, M | 1 |
| Mura, A | 1 |
| Chiou, GC | 1 |
| Chen, YJ | 1 |
| Monteiro, Mdo C | 1 |
| Soares, CG | 1 |
| Décio, RC | 1 |
| Nehlig, A | 1 |
| Vergnes, M | 1 |
| Marescaux, C | 1 |
| Boyet, S | 1 |
| Kaneda, H | 2 |
| Shirakawa, O | 1 |
| Dale, J | 1 |
| Goodman, L | 2 |
| Bachus, SE | 1 |
| Auchus, AP | 1 |
| Pickel, VM | 1 |
| Ujihara, H | 1 |
| Xie, RM | 1 |
| Ishihara, K | 1 |
| Fujita, Y | 1 |
| Yoshimura, M | 1 |
| Kishimoto, T | 1 |
| Serikawa, T | 1 |
| Yamada, J | 1 |
| Takaori, S | 1 |
| Rupniak, NM | 3 |
| Tye, SJ | 2 |
| Iversen, SD | 2 |
| Messiha, FS | 1 |
| Dale, JM | 1 |
| Kaneda, N | 1 |
| Miyamoto, K | 1 |
| Johnson, CJ | 1 |
| McCullough, LD | 1 |
| Steinpreis, RE | 1 |
| Keck, PE | 1 |
| Seeler, DC | 1 |
| Pope, HG | 1 |
| McElroy, SL | 1 |
| Steventon, MJ | 1 |
| Boyce, S | 1 |
| Ferré, S | 1 |
| Guix, T | 1 |
| Prat, G | 1 |
| Jane, F | 1 |
| Casas, M | 1 |
| Liao, RM | 1 |
| Skjoldager, P | 1 |
| See, RE | 2 |
| Ellison, G | 1 |
| Aravagiri, M | 1 |
| Ellison, GD | 1 |
| Marco, LA | 1 |
| Pendleton, R | 1 |
| Reed, TF | 1 |
| Brigham, TE | 1 |
| Aldes, LD | 1 |
| Chronister, RB | 1 |
| Vamvakides, A | 1 |
| Tanner, CM | 1 |
| Häggström, JE | 1 |
| Domino, EF | 1 |
| Russell, KH | 1 |
| Hagenmeyer-Houser, SH | 1 |
| Sanberg, PR | 1 |
| Sasaki, M | 1 |
| Hashizume, K | 1 |
| Manaka, S | 1 |
| Takakura, K | 1 |
| Chahl, LA | 1 |
| Kavanagh, CA | 1 |
| Corlis, A | 1 |
| Barros, HM | 1 |
| Leite, JR | 1 |
| Paulseth, JE | 1 |
| Schmajuk, NA | 1 |
| Chen, YC | 1 |
| Chesire, RM | 1 |
| Poirier, LJ | 2 |
| Langelier, P | 1 |
| Bédard, P | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Thulin, CA | 1 |
| Blom, S | 1 |
| Hedeman, LS | 1 |
| Sil, R | 1 |
| Cui, Y | 1 |
| Chen, G | 1 |
| Yao, L | 1 |
| Zhang, N | 1 |
| Liu, Z | 1 |
| Li, Q | 1 |
| Cui, Z | 1 |
| Zhang, K | 1 |
| Li, P | 1 |
| Cheng, Y | 1 |
| Zhang, S | 1 |
| Chen, X | 1 |
| Scelza, MZ | 1 |
| Campos, CA | 1 |
| Scelza, P | 1 |
| Adeodato, CS | 1 |
| Barbosa, IB | 1 |
| de Noronha, F | 1 |
| Montalli, V | 1 |
| Napimoga, M | 1 |
| de Araújo, VC | 1 |
| Alves, GG | 1 |
| Li, DZ | 1 |
| Jiang, J | 1 |
| Miao, Y | 1 |
| Virley, D | 1 |
| Hadingham, SJ | 1 |
| Roberts, JC | 1 |
| Farnfield, B | 1 |
| Elliott, H | 1 |
| Whelan, G | 1 |
| Golder, J | 1 |
| David, C | 1 |
| Parsons, AA | 1 |
| Hunter, AJ | 1 |
| Chen, H | 1 |
| Teixeira, FB | 1 |
| Ritter, AL | 1 |
| Levin, L | 1 |
| Trope, M | 1 |
| Lu, JH | 1 |
| Chang, Y | 1 |
| Sung, HW | 1 |
| Chiu, YT | 1 |
| Yang, PC | 1 |
| Hwang, B | 1 |
| Thorgeirsson, A | 1 |
| Fregert, S | 1 |
| Huan, Q | 1 |
| Gao, Z | 1 |
| Wu, P | 1 |
| Xiao, H | 1 |
| Peng, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Atlas Cedarwood Essential Oil Aromatherapy on Sleep Quality Among Patients With Coronary Heart Disease: a Randomized Controlled Trial[NCT03830554] | 96 participants (Actual) | Interventional | 2018-07-30 | Completed | |||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease[NCT01341431] | Phase 2 | 50 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis[NCT05282277] | Phase 4 | 103 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | ||
| Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response[NCT03495024] | Phase 4 | 10 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia[NCT00621634] | Phase 2 | 40 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| Differences in Voxel-based Morphometry of Different Brain Structures in Patients With Mood Disorder Bipolar Mania in Comparison to Morphometry of Nrmal Controls[NCT03181698] | 45 participants (Actual) | Observational | 2017-09-22 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for haloperidol and Disease Models, Animal
| Article | Year |
|---|---|
Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.
Topics: Animals; Catalepsy; Disease Models, Animal; Haloperidol; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Disease M | 2012 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
[Effect of antipsychotics on glutaminergic neural transmission in the animal model].
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Disease Models, Animal; Haloperidol; Humans; Long-T | 2004 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Di | 1983 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relations | 2000 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease M | 1986 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlor | 1974 |
1 trial available for haloperidol and Disease Models, Animal
| Article | Year |
|---|---|
Clozapine in tardive dyskinesia: observations from human and animal model studies.
Topics: Adult; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dyskinesia, Drug-Induced; F | 1994 |
506 other studies available for haloperidol and Disease Models, Animal
| Article | Year |
|---|---|
Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists.
Topics: Animals; Bromocriptine; Cycloheptanes; Disease Models, Animal; Hydroxydopamines; Male; Oxidopamine; | 1984 |
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evalua | 2001 |
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug | 2006 |
Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
Topics: Acetamides; Animals; Antipsychotic Agents; Combinatorial Chemistry Techniques; Disease Models, Anima | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; | 2008 |
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.
Topics: Animals; Carbazoles; Disease Models, Animal; Dopamine Agonists; Rats; Receptor, Serotonin, 5-HT1A; R | 2009 |
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine Agonists; Quinolones; Receptor, Sero | 2010 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relatio | 2012 |
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Disease Models, Animal; Models, | 2015 |
Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.
Topics: Analgesics, Non-Narcotic; Animals; Chemistry Techniques, Synthetic; Disease Models, Animal; Dose-Res | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Respo | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Receptors, Serotonin; St | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dopamine Agonists; Drug Design; Drug Evaluation, | 2021 |
Therapeutic potential of TAK-071, a muscarinic M
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; CHO Cells; Cognition; Cognitive Dysfunction; C | 2021 |
Haloperidol and methylphenidate alter motor behavior and responses to conditioned fear of Carioca Low-conditioned Freezing rats.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Conditioning, Psy | 2021 |
Antidepressant, anti-amnesic and vasoprotective effect of Bombax costatum Pellegr. & Vuillet aqueous stem bark extract on chronic mild unpredictable stress induced in rat.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Behavior, Animal; Bombax; Depression; Depressi | 2022 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.
Topics: Acetylcholinesterase; Animals; Diarylheptanoids; Disease Models, Animal; Haloperidol; Parkinson Dise | 2023 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Haloperidol; Humans; Mice; Mice, Inbred C57BL | 2022 |
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.
Topics: Aged; Aged, 80 and over; Aging; Animals; Antipsychotic Agents; Autopsy; Datasets as Topic; Disease M | 2023 |
Haloperidol alters neurotrophic factors and epigenetic parameters in an animal model of schizophrenia induced by ketamine.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Epigenesis, Genetic; Glial Cell | 2023 |
Pharmacological and proteomic analyses of neonatal polyI:C-treated adult mice.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Animals, Newborn; Antipsychotic Agents; Clozapine; Disease | 2019 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
Haloperidol-induced hypokinesia in rats is differentially affected by the light/dark phase, age, and melatonin.
Topics: Age Factors; Animals; Behavior, Animal; Central Nervous System Depressants; Disease Models, Animal; | 2020 |
Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson's disease.
Topics: Albizzia; Animals; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Haloperidol; Motor Ski | 2019 |
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosa | 2020 |
Preference for vigorous exercise versus sedentary sucrose drinking: an animal model of anergia induced by dopamine receptor antagonism.
Topics: Animals; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Male; Maze Learning; Mice; Motiv | 2020 |
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment.
Topics: Animals; Antipsychotic Agents; Brain; Cannabidiol; Cerebrovascular Circulation; Disease Models, Anim | 2020 |
Playback of 50-kHz ultrasonic vocalizations overcomes psychomotor deficits induced by sub-chronic haloperidol treatment in rats.
Topics: Acoustic Stimulation; Animals; Disease Models, Animal; Dopamine Antagonists; Exploratory Behavior; H | 2020 |
Regulatory effects of Ningdong granule on microglia-mediated neuroinflammation in a rat model of Tourette's syndrome.
Topics: Animals; Chemokine CCL2; Corpus Striatum; Disease Models, Animal; Drugs, Chinese Herbal; Haloperidol | 2020 |
Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Topics: Animals; Benzazepines; Cocaine; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibi | 2020 |
Investigation of anti-Parkinson activity of dicyclomine.
Topics: Animals; Dicyclomine; Disease Models, Animal; Dopamine; Haloperidol; Mice; Paraquat; Parkinson Disea | 2022 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; | 2020 |
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Arginine; Behavior, Animal; Catalepsy; Disease Models, Animal; Di | 2021 |
Synergistic interaction between haloperidol and gabapentin in a model of neuropathic nociception in rat.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug | 2021 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Ab | 2021 |
Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats.
Topics: Animals; Anxiety; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Male; Rats | 2020 |
Haloperidol potentiates antinociceptive effects of morphine and disrupt opioid tolerance.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergis | 2021 |
Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesias; Flavanones; Haloperidol; Humans; | 2021 |
Discovery and optimization of a novel CNS penetrant series of mGlu
Topics: Allosteric Regulation; Animals; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; | 2021 |
Two novel mouse models mimicking minor deletions in 22q11.2 deletion syndrome revealed the contribution of each deleted region to psychiatric disorders.
Topics: 22q11 Deletion Syndrome; Animals; Base Sequence; Behavior, Animal; Circadian Rhythm; Conditioning, C | 2021 |
Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Haloperidol; Phenotype; Rats; Rotenone; Schizophr | 2021 |
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis.
Topics: Animals; Antipsychotic Agents; Autophagy; Autophagy-Related Proteins; Axons; Biomarkers; Clozapine; | 2021 |
Obesity Potentiates the Risk of Drug-Induced Long QT Syndrome - Preliminary Evidence from WNIN/Ob Spontaneously Obese Rat.
Topics: Adiposity; Animals; Antipsychotic Agents; Cardiomegaly; Disease Models, Animal; Female; Haloperidol; | 2021 |
Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats.
Topics: Animals; Antioxidants; Behavior, Animal; Catalase; Corpus Striatum; Disease Models, Animal; Glutathi | 2017 |
Novel therapeutic approaches of natural oil from black seeds and its underlying mechanisms against kidney dysfunctions in haloperidol-induced male rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Electrolytes; Haloperidol; Kidney; Lipid Pero | 2017 |
The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression.
Topics: Affect; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Cell Survival; Cloza | 2017 |
Comparable impediment of cognitive function in female and male rats subsequent to daily administration of haloperidol after traumatic brain injury.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain Injuries, Traumatic; Cognition; Disease M | 2017 |
An ethanolic extract of Desmodium adscendens exhibits antipsychotic-like activity in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Ethanol; Fabaceae; Fe | 2017 |
Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Catalepsy; Chlorpromazine; | 2017 |
Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Dendritic Spines; Disease Models, Animal; Dopamine; | 2017 |
Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits.
Topics: Animals; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; CA1 Region, Hippocampal | 2018 |
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic; Disease Mod | 2017 |
Awakenings in rats by ultrasounds: A new animal model for paradoxical kinesia.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2018 |
Role of dopamine on functional recovery in the contralateral hemisphere after focal stroke in the somatosensory cortex.
Topics: Animals; Aripiprazole; Brain; Disease Models, Animal; Dopamine; Functional Laterality; Haloperidol; | 2018 |
Spontaneous recovery of traumatic brain injury-induced functional deficits is not hindered by daily administration of lorazepam.
Topics: Animals; Antipsychotic Agents; Brain Injuries, Traumatic; Cognition; Conditioning, Psychological; Di | 2018 |
Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Biological Products; D | 2018 |
Antiallergic and antihistaminic actions of Ceasalpinia bonducella seeds: Possible role in treatment of asthma.
Topics: Acetates; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Caesalpinia; Catalepsy; Cell Degranu | 2018 |
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesias; Glutamates; Haloperidol; Lipid Peroxi | 2018 |
Haloperidol-induced catalepsy is ameliorated by deep brain stimulation of the inferior colliculus.
Topics: Animals; Antipsychotic Agents; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperido | 2018 |
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
Topics: Administration, Oral; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Benzodiazepines; Catal | 2018 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Dise | 2018 |
Paradoxical kinesia induced by appetitive 50-kHz ultrasonic vocalizations in rats depends on glutamatergic mechanisms in the inferior colliculus.
Topics: Animals; Appetitive Behavior; Catalepsy; Diazepam; Disease Models, Animal; GABA Modulators; Glutamic | 2018 |
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neu | 2018 |
Altered dopaminergic regulation of the dorsal striatum is able to induce tic-like movements in juvenile rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Down-Regulation; Haloperidol; M | 2018 |
Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopamine Antag | 2018 |
Albizia zygia root extract exhibits antipsychotic-like properties in murine models of schizophrenia.
Topics: Albizzia; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Cognition; Disease Models, Ani | 2018 |
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Dose-Re | 2018 |
State-dependent effects of the D
Topics: Animals; Apomorphine; Aripiprazole; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; | 2019 |
Na
Topics: Animals; Chlorpromazine; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Genes, fos; Halop | 2019 |
Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Ascorbic Acid; Behavior, Ani | 2018 |
Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.
Topics: Animals; Antipsychotic Agents; Apathy; Behavior, Animal; Biperiden; Cognitive Dysfunction; Disease M | 2019 |
Impact of nuclear distribution element genes in the typical and atypical antipsychotics effects on nematode Caenorhabditis elegans: Putative animal model for studying the pathways correlated to schizophrenia.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Behavior, Animal; Caenorhabditis elega | 2019 |
Influence of aversive stimulation on haloperidol-induced catalepsy in rats.
Topics: Affect; Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopam | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Fe | 2019 |
High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation.
Topics: Actins; Animals; Calcium; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Drug Reposi | 2019 |
Role of Aqueous Extract of the Wood Ear Mushroom, Auricularia polytricha (Agaricomycetes), in Avoidance of Haloperidol-lnduced Catalepsy via Oxidative Stress in Rats.
Topics: Animals; Antipsychotic Agents; Basidiomycota; Catalepsy; Disease Models, Animal; Fruiting Bodies, Fu | 2019 |
Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment.
Topics: Animals; Behavior, Animal; Cognition; Discrimination Learning; Disease Models, Animal; Exploratory B | 2019 |
Assessing Reality Testing in Mice Through Dopamine-Dependent Associatively Evoked Processing of Absent Gustatory Stimuli.
Topics: Animals; Antipsychotic Agents; Association Learning; Auditory Perception; Behavior, Animal; Cerebral | 2020 |
Isoallopregnanolone reduces tic-like behaviours in the D1CT-7 mouse model of Tourette syndrome.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Finasteride; Ha | 2020 |
Differential effects of antipsychotic drugs on contrast response functions of retinal ganglion cells in wild-type Sprague-Dawley rats and P23H retinitis pigmentosa rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Male; Photic Stimulat | 2019 |
Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Ma | 2019 |
Asenapine maleate normalizes low frequency oscillatory deficits in a neurodevelopmental model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Delta Rhythm; Dibenzocycloheptenes; Disease Models, | 2019 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia | 2013 |
Unique pharmacological actions of atypical neuroleptic quetiapine: possible role in cell cycle/fate control.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Astrocytes; Cell Cycle; Dibenzothiazepines; Dis | 2013 |
Involvement of transmitters in the anxiolytic action of urocortin 3 in mice.
Topics: Analysis of Variance; Animals; Anxiety; Atropine; Bicuculline; Disease Models, Animal; Dose-Response | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia | 2013 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; H | 2013 |
Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free | 2013 |
[Changes in neuroglial interactions in the cerebral nigrostriatal structures in a model of dopamine system dysfunction].
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine Antagonists; Haloperidol; Neuroglia; Parkinson D | 2013 |
Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Chromatography, Liquid; Disease Models | 2013 |
Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
Topics: Adenosine A2 Receptor Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripipraz | 2014 |
Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison.
Topics: Animals; Disease Models, Animal; Dopamine Antagonists; Electromyography; Haloperidol; Jaw; Male; Mot | 2014 |
Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Central Nervous System Sensitization; | 2014 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Mod | 2013 |
Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Area Under Curve; Brain; Clozapine; Disease Mod | 2014 |
Evaluation of the antipsychotic potential of aqueous fraction of Securinega virosa root bark extract in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Dose-Response Relatio | 2014 |
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Diazepam; Disea | 2014 |
The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Cholinergic Antagonists; Disease Mod | 2014 |
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cyclic AMP; Disease Models, Ani | 2014 |
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Recepto | 2014 |
Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Clozapine; Disease Models, Animal; Dopamine Antagonists | 2014 |
Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Antagonists; D | 2014 |
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Topics: Amino Acid Transport System X-AG; Anilides; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; C | 2014 |
Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; DNA Methylation; Gene Expression; | 2014 |
The sigma-1 receptor agonist 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) protects against newborn excitotoxic brain injury by stabilizing the mitochondrial membrane potential in vitro and inhibiting microglial activation in vivo.
Topics: Animals; Animals, Newborn; Apoptosis; Apoptosis Inducing Factor; Brain Injuries; Caspase 3; Disease | 2014 |
Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antidepressive Agent | 2014 |
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response | 2015 |
Reversal of haloperidol induced motor deficits in rats exposed to repeated immobilization stress.
Topics: Adaptation, Psychological; Animals; Brain; Disease Models, Animal; Haloperidol; Male; Motor Activity | 2014 |
Haloperidol-induced extra pyramidal symptoms attenuated by imipramine in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain; Disease Models, Animal; Dyskines | 2014 |
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cognition Disorders; Disease Model | 2014 |
Dual regulating effects of gastrodin on extracellular dopamine concentration in rats models of Tourette's syndrome.
Topics: Animals; Apomorphine; Benzyl Alcohols; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine P | 2015 |
Haloperidol treatment at pre-exposure phase reduces the disturbance of latent inhibition in rats with neonatal ventral hippocampus lesions.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Dise | 2014 |
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine | 2015 |
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice.
Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Centr | 2015 |
-NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Calcium; Cognition Disorders; Disease Models, Animal; Disease | 2015 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epi | 2015 |
Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients?
Topics: Animals; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Inferior Colliculi; | 2015 |
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol | 2015 |
Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Atherosclerosis; ATP Bind | 2015 |
Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Dietary Sucrose; Disease | 2015 |
Neuro-anatomic mapping of dopamine D1 receptor involvement in nicotine self-administration in rats.
Topics: Animals; Benzazepines; Brain Mapping; Catheters, Indwelling; Cohort Studies; Disease Models, Animal; | 2015 |
Inhibition of 14-3-3 Proteins Leads to Schizophrenia-Related Behavioral Phenotypes and Synaptic Defects in Mice.
Topics: 14-3-3 Proteins; Animals; Antipsychotic Agents; Behavior, Animal; Catenins; Cerebral Cortex; Clozapi | 2015 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas | 2015 |
Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.
Topics: Animals; Brain; Chemistry, Pharmaceutical; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopa | 2015 |
A Methionine-Induced Animal Model of Schizophrenia: Face and Predictive Validity.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Depression; Disease Models, Animal; Ha | 2015 |
Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Antipsychotic Agents; | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Int | 2015 |
Efficacy and Mechanism of Action of Yiru Tiaojing Granule Against Hyperprolactinemia In Vitro and In Vivo.
Topics: Animals; Brain; Bromocriptine; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease | 2015 |
Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Gene Expression; Glycine Plasma Me | 2015 |
Inhalation of Cedrus atlantica essential oil alleviates pain behavior through activation of descending pain modulation pathways in a mouse model of postoperative pain.
Topics: Administration, Inhalation; Adrenergic alpha-2 Receptor Antagonists; alpha-Methyltyrosine; Analgesic | 2015 |
Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms.
Topics: Animals; Anti-Dyskinesia Agents; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Ginkgo | 2016 |
Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
Topics: Amisulpride; Animals; Anti-Dyskinesia Agents; Benzothiazoles; Disease Models, Animal; Dopamine Agoni | 2016 |
LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Ketamine; Male; Memor | 2016 |
Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.
Topics: Action Potentials; Animals; Basal Ganglia; Bee Venoms; Catalepsy; Disease Models, Animal; Dopamine A | 2015 |
High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Central Ner | 2015 |
Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Disease Mode | 2016 |
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Disease Models, Animal; Female; Gene Expression; Hal | 2016 |
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Topics: Amino Acids; Animals; Antipsychotic Agents; Benzodiazepines; Bridged Bicyclo Compounds, Heterocyclic | 2016 |
High estrogen and chronic haloperidol lead to greater amphetamine-induced BOLD activation in awake, amphetamine-sensitized female rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Estradiol; Female; Hal | 2016 |
Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized cata
Topics: Analysis of Variance; Animals; Apomorphine; Catalepsy; Conditioning, Classical; Disease Models, Anim | 2016 |
Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
Topics: Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; G | 2016 |
The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Benzofurans; Brain-Derived Neurotrophic Factor; | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cata | 2016 |
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Channelrhodopsins; Choline O-Acetyltransferase; Cholinergic Neurons; | 2016 |
Effects of Antipsychotic Drugs Haloperidol and Clozapine on Visual Responses of Retinal Ganglion Cells in a Rat Model of Retinitis Pigmentosa.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Haloperidol; Rats; Retinal Ganglio | 2016 |
Effect of L-pGlu-(1-benzyl)-l-His-l-Pro-NH
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Ischemia; Catalepsy; Cell Death; Diseas | 2016 |
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Catalepsy; Chick Embryo; Disease Models, | 2017 |
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
Topics: alpha-Tocopherol; Animals; Antioxidants; Antipsychotic Agents; bcl-2-Associated X Protein; Brain; Di | 2016 |
The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Brain; Cannabinoid Receptor Ago | 2017 |
Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Disease Models, Animal; Disks Large Homolog 4 Protein; F | 2017 |
Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain; Disease Models, Animal; Ha | 2016 |
Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Disea | 2008 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus | 2008 |
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clomipramine; Clozapine; Disea | 2008 |
Behavioral effects of 1-(m-chlorophenyl)piperazine (m-CPP) in a rat model of tardive dyskinesia.
Topics: Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-I | 2008 |
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Mode | 2008 |
An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relatio | 2008 |
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Attention; Cholinergic Antagonists; Clozapine; Cognition Disorders; C | 2009 |
Evaluation of the repeated open-space swim model of depression in the mouse.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.
Topics: Age Factors; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Catalep | 2008 |
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Antip | 2010 |
Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; G | 2009 |
Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Basal Ganglia Diseases; Behavior, Animal; Brain; Di | 2008 |
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Catalepsy; Disease Models, Animal; Drug Design; Drug Eva | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous | 2009 |
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Topics: Acetylcysteine; Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; Animals, Newborn; | 2009 |
Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Disease Models, Animal; | 2009 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease M | 2009 |
Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine | 2009 |
Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.
Topics: Analysis of Variance; Animals; Brain; Capsaicin; Disease Models, Animal; Dopamine Antagonists; Dose- | 2009 |
Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats.
Topics: Analysis of Variance; Animals; Chloroquinolinols; Corpus Striatum; Disease Models, Animal; Dopamine; | 2009 |
Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Topics: Animals; Antipsychotic Agents; Blotting, Western; Brain; Disease Models, Animal; Haloperidol; Humans | 2009 |
Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Behavior; Catalepsy; Cell Line; Disease Models, Anima | 2009 |
Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Behavior, Animal; Benzene Derivatives; Caffeine; Diseas | 2009 |
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship | 2009 |
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2010 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
Does haloperidol have side effects on histological and stereological structure of the rat kidneys?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Admini | 2009 |
The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats.
Topics: Aging; Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopam | 2010 |
Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain Ischemia; Corpus Striatum; Disease Models, An | 2010 |
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Apomorphine; Benzhydryl Compounds; Catalepsy; Disease Models, Animal | 2010 |
The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Conditioning, Operant; C | 2010 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2010 |
A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.
Topics: Amphetamine; Animals; Bupropion; Clozapine; Conditioning, Psychological; Disease Models, Animal; Dop | 2010 |
Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension.
Topics: Analysis of Variance; Animals; Blood Pressure; Bradykinin B1 Receptor Antagonists; Brain; Disease Mo | 2010 |
Prefrontal inositol triphosphate is molecular correlate of working memory in nonhuman primates.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium; Calcium Signaling; Central Nervous System Stimu | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dibenzothiazepines; Disease Models, Animal; Dop | 2011 |
Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?
Topics: Amphetamine; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dopamine; Dopamine Up | 2010 |
Haloperidol normalized prenatal vitamin D depletion-induced reduction of hippocampal cell proliferation in adult rats.
Topics: Animals; Antipsychotic Agents; Cell Proliferation; Disease Models, Animal; Female; Haloperidol; Hipp | 2010 |
Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia.
Topics: Animals; Benzoxazoles; Cerebral Cortex; Conditioning, Operant; Corticosterone; Disease Models, Anima | 2010 |
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.
Topics: Adrenergic Agents; Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Antipsychotic Agen | 2010 |
Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cell Count; Dependovirus; Disease Models, Animal; | 2010 |
The effects of clozapine on quinpirole-induced non-regulatory drinking and prepulse inhibition disruption in rats.
Topics: Animals; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic Factor; Clozapine; Disease Models, | 2010 |
Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Deep Brain Stimulation; Disease Models, Animal; Entopeduncular Nucleus; Exploratory Behavio | 2011 |
Neonatal ventral hippocampus lesion induces increase in nitric oxide [NO] levels which is attenuated by subchronic haloperidol treatment.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Drug Administration Schedule; Female; Haloperidol | 2010 |
Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationsh | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine | 2011 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagoni | 2011 |
Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Benzhydryl Compounds; Discrimination, Ps | 2010 |
Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; | 2011 |
Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Globus P | 2010 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines | 2011 |
Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.
Topics: Alkaloids; Analysis of Variance; Animals; Apoptosis; Behavior, Animal; Benzodioxoles; Caspase 3; Col | 2011 |
Cholinergic depletion in the nucleus accumbens: effects on amphetamine response and sensorimotor gating.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Cholin | 2011 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chemical Phenomena; Disease Models, Animal; Dyskinesia, | 2011 |
Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Topics: Animals; Basal Ganglia Diseases; Carya; Catalepsy; Disease Models, Animal; Haloperidol; Male; Moveme | 2011 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease | 2011 |
Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Clomipramine; Compuls | 2011 |
Characterizing the spontaneous blink generator: an animal model.
Topics: Adult; Animals; Apomorphine; Blinking; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonis | 2011 |
Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model.
Topics: Animals; Basal Ganglia Diseases; Disease Models, Animal; Female; Gene Expression Regulation; Haloper | 2012 |
Behavioral changes induced by long-term proline exposure are reversed by antipsychotics in zebrafish.
Topics: 1-Pyrroline-5-Carboxylate Dehydrogenase; Amino Acid Metabolism, Inborn Errors; Animals; Antipsychoti | 2012 |
The effect of haloperidol on maternal behavior in WAG/Rij rats and its consequences in the offspring.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anti-Dyskinesia Agents; Brain Waves; D | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
Topics: Alkaloids; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Re | 2012 |
An animal model to study the molecular basis of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apoptosis; Behavior, Animal; Caspase 3; Clozapine; Disease Models, An | 2012 |
Effects of sertraline on experimental mouse models of psychosis.
Topics: Animals; Antidepressive Agents; Apomorphine; Catalepsy; Dextroamphetamine; Disease Models, Animal; D | 2012 |
Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Topics: Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopamine Anta | 2012 |
Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment.
Topics: Aged; Alleles; Animals; Antipsychotic Agents; Cerebellum; Clozapine; Disease Models, Animal; Excitat | 2013 |
Sedative, antiepileptic and antipsychotic effects of Viscum album L. (Loranthaceae) in mice and rats.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Epil | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Di | 2013 |
Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis.
Topics: Animals; Antigens, Nuclear; Apoptosis; Cell Nucleus; Cell Proliferation; Cells, Cultured; Disease Mo | 2012 |
Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Topics: Animals; Anisoles; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Depression; | 2012 |
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Topics: Aging; Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Rel | 2012 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Effect of zinc in animal models of anxiety, depression and psychosis.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Agents; Chlorides; Depression; Disease Mo | 2012 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperi | 2012 |
Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Frontal Lobe; | 2012 |
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocain | 2013 |
A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Dark Ada | 2012 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Halo | 2012 |
A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain; Cell Cycle Proteins; Clozapine; Disease Models, Animal; Gene E | 2012 |
Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.
Topics: 5,7-Dihydroxytryptamine; Amphetamines; Analysis of Variance; Animals; Antipsychotic Agents; Autoradi | 2012 |
Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia.
Topics: Animals; Bromocriptine; Cell Line; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonist | 2012 |
Antifibrotic and anti-inflammatory activity of a neuroleptic drug on the model of pulmonary fibrosis.
Topics: Administration, Inhalation; Animals; Antipsychotic Agents; Bleomycin; Cell Differentiation; Connecti | 2012 |
[Morphochemical characteristics of hippocampal neuron's response to the hypofunction of the dopaminergic system].
Topics: Animals; Anti-Dyskinesia Agents; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Cell Nucleus; Cyt | 2012 |
Blood-brain barrier unlocked.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Blood-Brain Barrier; Catalepsy; | 2012 |
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Down-Regulation; | 2013 |
Differential effects of antipsychotics on lateral bias and social attention in female rats.
Topics: Animals; Antipsychotic Agents; Attention; Behavior, Animal; Clozapine; Disease Models, Animal; Femal | 2013 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psycho | 2012 |
Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesi | 2012 |
Enhanced reward-facilitating effects of d-amphetamine in rats in the quinpirole model of obsessive-compulsive disorder.
Topics: Analysis of Variance; Animals; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphe | 2013 |
Aquaporin-4 knockout abolishes apomorphine-induced tardive dyskinesia following chronic treatment with neuroleptics.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Aquaporin 4; | 2012 |
Intra-orbitofrontal cortex injection of haloperidol removes the beneficial effect of methylphenidate on reversal learning of spontaneously hypertensive rats in an attentional set-shifting task.
Topics: Animals; Attention; Attention Deficit and Disruptive Behavior Disorders; Disease Models, Animal; Dop | 2013 |
Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Exploratory Behavior; Halop | 2013 |
Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.
Topics: Animals; Behavior, Animal; Clomipramine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Flu | 2013 |
Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration.
Topics: Animals; Behavior, Animal; Benzazepines; Decision Making; Disease Models, Animal; Dopamine Antagonis | 2013 |
Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Disease Models, Animal; Excitatory Amino Aci | 2013 |
Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.
Topics: Administration, Oral; Age Factors; Animals; Animals, Newborn; Corpus Striatum; Disease Models, Anima | 2002 |
Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism.
Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Audito | 2003 |
Effect of Emblica officinalis tannoids on a rat model of tardive dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Antioxidants; Brain; Disease Models, Animal; Dyski | 2000 |
Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Haloper | 2003 |
Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Conditioning, Psychological; Disease Mod | 2003 |
Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Topics: Administration, Oral; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2003 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2003 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Di | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Resp | 2003 |
The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.
Topics: Animals; Ataxia; Behavior, Animal; Catalepsy; Diamines; Disease Models, Animal; Dizocilpine Maleate; | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Cebus; Clozapine; Disease Mod | 2003 |
Tail-swing behavior: a novel animal model for anxiety.
Topics: Animals; Anxiety; Behavior, Animal; Desipramine; Diazepam; Disease Models, Animal; Haloperidol; Immo | 2003 |
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia.
Topics: Aging; Amphetamine; Animals; Central Nervous System Stimulants; Clozapine; Corpus Striatum; Disease | 2003 |
Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Comorbidity; Corpus Striatum; Disease Models | 2003 |
Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action.
Topics: Animals; Antipsychotic Agents; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2003 |
Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Catalase; Disease Models, Anim | 2003 |
Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Drug Adm | 2003 |
The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Drug Administration Routes; | 2003 |
Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cell Survival; Disease Models, Ani | 2004 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caff | 2003 |
The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response | 2004 |
[Altered behavioral response to centrally acting drugs in mice lacking PACAP].
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Model | 2003 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2004 |
Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; | 2004 |
Motor disturbances in mice with deficiency of the sodium channel gene Scn8a show features of human dystonia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Biperiden; Brain; Diazepam; Disease Models, Animal | 2003 |
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Cycloserine; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycine; Haloperidol; Mastic | 2004 |
Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liqu | 2004 |
Glutamatergic regulation of long-term grafts of fetal lateral ganglionic eminence in a rat model of Huntington's disease.
Topics: Animals; Brain Injuries; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dizo | 2004 |
Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression.
Topics: Animals; Antipsychotic Agents; Binding Sites; Clozapine; Disease Models, Animal; Drug Administration | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia.
Topics: Animals; Antioxidants; Cabergoline; Cell Death; Cell Hypoxia; Cell Line, Transformed; Cell Line, Tum | 2004 |
Atypical antipsychotic profile of flunarizine in animal models.
Topics: Administration, Oral; Animals; Catalepsy; Dextroamphetamine; Disease Models, Animal; Dizocilpine Mal | 2005 |
Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzoates; Biphenyl Compounds; Disease Models, | 2004 |
Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding Sites; C | 2004 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio | 2005 |
Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.
Topics: Aging; Animals; Disease Models, Animal; Epithelial Cells; Haloperidol; Hyperprolactinemia; Male; Pro | 2004 |
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Dyskines | 2005 |
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Dopamine A | 2005 |
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
Topics: Adaptor Proteins, Vesicular Transport; Aged; Animals; Antipsychotic Agents; Behavior, Animal; Cognit | 2005 |
A putative animal model of the "prodromal" state of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Anim | 2005 |
Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.
Topics: alpha-Tocopherol; Animals; Ascorbic Acid; Catalepsy; Disease Models, Animal; Dopamine Antagonists; D | 2005 |
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Clozapine; De | 2005 |
Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dose-Response | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Mod | 2005 |
Abnormally persistent latent inhibition induced by lesions to the nucleus accumbens core, basolateral amygdala and orbitofrontal cortex is reversed by clozapine but not by haloperidol.
Topics: Amygdala; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Drinking Behavior; Halop | 2006 |
Cortical gene expression in the neonatal ventral-hippocampal lesion rat model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Disease Models, Animal; Doublecortin Protein; Front | 2005 |
Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Bupropion; Disease Models, Animal; Dopamine Upta | 2005 |
MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; | 2005 |
Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity in the rat.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Electric Stimulation; H | 2005 |
Novel oral drug administration in an animal model of neuroleptic therapy.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Brain; Clozapine | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2005 |
The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Behavior, | 2006 |
A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Diazepam; Disease Models, Animal; Dopamine; Electrophysio | 2005 |
Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Disease Models, Animal; Female; Fluoxetine; Haloperidol; | 2005 |
Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Buspirone; Chlordiazepoxide; Diazepam; Disea | 2006 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies | 2007 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2006 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; | 2006 |
Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizoc | 2006 |
Linking animal models of psychosis to computational models of dopamine function.
Topics: Action Potentials; Amphetamine; Animals; Computer Simulation; Conditioning, Classical; Disease Model | 2007 |
Targeting pain-suppressed behaviors in preclinical assays of pain and analgesia: effects of morphine on acetic acid-suppressed feeding in C57BL/6J mice.
Topics: Acetic Acid; Analgesics, Opioid; Animals; Behavior, Animal; Disease Models, Animal; Dopamine Antagon | 2006 |
Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.
Topics: Acoustic Stimulation; Amphetamine; Animals; Auditory Threshold; Brain Stem; Central Nervous System S | 2006 |
Effects of diphenyl-diselenide on orofacial dyskinesia model in rats.
Topics: Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 2006 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Die | 2006 |
Efficacy of olanzapine and haloperidol in an animal model of mania.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Bipolar Diso | 2006 |
Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid.
Topics: Animals; Brain; Catalepsy; Cell Line, Transformed; Disease Models, Animal; Dopamine Antagonists; Enz | 2006 |
Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Topics: Adenosine; Akathisia, Drug-Induced; Animals; Antioxidants; Behavior, Animal; Brain; Caffeine; Catala | 2006 |
Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Drug Combinat | 2007 |
Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Eating; Hallucinogens; Haloperidol | 2007 |
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system.
Topics: Animals; Antibodies, Anti-Idiotypic; Antidepressive Agents, Second-Generation; Autoimmunity; Brain; | 2007 |
Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia.
Topics: Animals; Brain Diseases, Metabolic; Cognition Disorders; Disease Models, Animal; Dopamine; Dopamine | 2007 |
Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme-Linked I | 2007 |
Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorder | 2007 |
Lack of effect of dopaminergic antagonists in a rodent model of peritoneal sepsis.
Topics: Animals; Biomarkers; Clozapine; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Inflammat | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzoth | 2007 |
Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striat | 2007 |
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Arginine Vasopressin; Clozapine; Deamino Argini | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; | 2007 |
Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice.
Topics: Animals; Antipsychotic Agents; Autoradiography; Baclofen; Brain; Clozapine; Disease Models, Animal; | 2007 |
Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Central Nervous S | 2007 |
Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1.
Topics: Animals; Antipsychotic Agents; Arousal; Attention; Behavior, Animal; Disease Models, Animal; Genes, | 2008 |
Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Topics: Akathisia, Drug-Induced; Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Disea | 2007 |
In hamsters dopamine D2 receptors affect ventilation during and following intermittent hypoxia.
Topics: Animals; Body Temperature; Carbon Dioxide; Carotid Body; Cricetinae; Disease Models, Animal; Domperi | 2007 |
Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo.
Topics: Age Factors; Animals; Antipsychotic Agents; Cell Count; Corpus Striatum; Disease Models, Animal; Dop | 2008 |
Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the tail suspension test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Cycloheptanes; Depressive Dis | 2008 |
[Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response].
Topics: Amphetamines; Animals; Disease Models, Animal; Dopamine; Fluoxetine; Haloperidol; Homovanillic Acid; | 2007 |
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Topics: Animals; Antipsychotic Agents; Brain Diseases; Control Groups; Disease Models, Animal; Dopamine; Dys | 2008 |
Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, An | 2008 |
Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Binding Sites; Brain; Diazepam; Dis | 2008 |
Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia.
Topics: Animals; Attention; Clozapine; Cognition; Cognition Disorders; Disease Models, Animal; Haloperidol; | 2008 |
The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Conditioning, Psychological; Disease | 2008 |
U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Chlorpromazine; Disease Models, Animal; Dyskinesia, Dru | 2007 |
Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Dopamine A | 2007 |
Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Depress | 2008 |
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2008 |
Gamma-aminobutyric acid and basal ganglia outflow pathways.
Topics: Animals; Basal Ganglia; Catalepsy; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Hum | 1984 |
Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Chlorpromazine; Di | 1980 |
Neuroleptic-induced acute dyskinesias in rhesus monkeys.
Topics: Acute Disease; Animals; Antipsychotic Agents; Benzamides; Disease Models, Animal; Dyskinesia, Drug-I | 1981 |
Animal models of tardive dyskinesias.
Topics: Animals; Antipsychotic Agents; Apomorphine; Chlorpromazine; Disease Models, Animal; Dyskinesia, Drug | 1983 |
Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Glutamate Decarboxy | 1983 |
[Effect of central effective substances on alcohol preference].
Topics: Alcohol Drinking; Alcoholism; Animals; Arecoline; Atropine; Central Nervous System Stimulants; Cypro | 1983 |
Parkinson's disease: studies with an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology; | 1984 |
Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Guinea Pigs | 1984 |
Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics.
Topics: Adrenal Medulla; Animals; Disease Models, Animal; Flupenthixol; Haloperidol; Hydroxydopamines; Male; | 1984 |
Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans.
Topics: Aging; Animals; Apomorphine; Brain Chemistry; Disease Models, Animal; Dopamine; Dystonia Musculorum | 1984 |
[Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)].
Topics: Adult; Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Drug | 1984 |
Norepinephrine-induced pulmonary petechiae in the rat: an experimental model with potential implications for sudden infant death syndrome.
Topics: Animals; Blood Pressure; Catecholamines; Disease Models, Animal; Haloperidol; Humans; Lung Diseases; | 1984 |
[The effects of chronic methamphetamine and single haloperidol injections on thiamine and its phosphate ester levels in the rat brain].
Topics: Animals; Brain; Disease Models, Animal; Haloperidol; Humans; Male; Methamphetamine; Rats; Rats, Inbr | 1984 |
Oral tardive dyskinesia in the rat.
Topics: Animals; Apomorphine; Bruxism; Dental Occlusion, Traumatic; Disease Models, Animal; Dyskinesia, Drug | 1983 |
LSD-potentiated apomorphine hypermotility: a model for differentiating antipsychotic drugs.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Disease Models, Animal; Drug Antagonism; Haloperido | 1983 |
Response to intracerebral dopamine injection as a model of schizophrenic symptomatology.
Topics: Animals; Brain Mapping; Corpus Striatum; Disease Models, Animal; Dopamine; Grooming; Haloperidol; Hu | 1983 |
Haloperidol-induced hyperactivity in neonatal rats: effect of lithium and stimulants.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Humans; H | 1982 |
MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
Topics: Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1982 |
Experimental tardive dyskinesia.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Macaca fascicularis; | 1982 |
Galloping induced by pontine tegmentum damage in rats: a form of "Parkinsonian festination" not blocked by haloperidol.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Locomotion; Male; Motor Activ | 1981 |
A new animal model for Tourette syndrome.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Haloperidol; Humans; Male; Nitriles | 1982 |
Hormonal interference in experimental models of depression.
Topics: Animals; Apomorphine; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Haloperidol; Hu | 1982 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Con | 1982 |
Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.
Topics: Animals; Baclofen; Brain Chemistry; Disease Models, Animal; Dopamine; Drug Interactions; Dyskinesia, | 1982 |
Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dyski | 1981 |
Further analysis of the specificity of a novel animal model of depression--effects of an antihistaminic, antipsychotic and anxiolytic compound.
Topics: Animals; Corticosterone; Depressive Disorder; Disease Models, Animal; Exploratory Behavior; Haloperi | 1982 |
Animal models of tardive dyskinesia [proceedings].
Topics: Animals; Cebidae; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans; Rats | 1981 |
The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Mastication; Motor A | 1995 |
Evidence for the involvement of histamine in the antidystonic effects of diphenhydramine.
Topics: Animals; Diphenhydramine; Disease Models, Animal; Dose-Response Relationship, Drug; Dystonia; Halope | 1995 |
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperi | 1995 |
Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment.
Topics: Animals; Brain Mapping; Disease Models, Animal; Haloperidol; Hippocampus; Limbic System; Male; Neura | 1995 |
Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats.
Topics: Analysis of Variance; Anesthesia; Animals; Disease Models, Animal; Dopamine; Haloperidol; Male; Micr | 1994 |
Amphetamine and haloperidol modulatory effects on Purkinje cell activity and on EEG power spectra in the acute rat model of epilepsy.
Topics: Amphetamine; Animals; Disease Models, Animal; Electroencephalography; Epilepsy; Haloperidol; Male; P | 1994 |
[The role of lipid peroxidation in the pathogenesis of neuropathological syndromes and in experimental therapy].
Topics: Animals; Antioxidants; Bemegride; Brain Chemistry; Chorea; Disease Models, Animal; Drug Evaluation, | 1994 |
Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Amino | 1994 |
The relationship between motor effects in rats following acute and chronic haloperidol treatment.
Topics: Acute Disease; Animals; Catalepsy; Chronic Disease; Disease Models, Animal; Dyskinesia, Drug-Induced | 1994 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol | 1994 |
Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations.
Topics: Animals; Behavior, Animal; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug I | 1993 |
Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder.
Topics: Animals; Clomipramine; Conditioning, Operant; Desipramine; Diazepam; Disease Models, Animal; Drinkin | 1993 |
Chronic haloperidol: neural correlates of motor disorders in an invertebrate model.
Topics: Animals; Catecholamines; Disease Models, Animal; Dopamine; Fluorescence; Glyoxylates; Haloperidol; H | 1994 |
[Intracerebral-ventricular injection of 4-aminopyridine induced convulsion in rabbits].
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Disease Models, Animal; Female; Haloperidol; Injections, | 1993 |
Differential effects of amphetamine and haloperidol on recovery after global forebrain ischemia.
Topics: Animals; Brain Ischemia; Dextroamphetamine; Disease Models, Animal; Gerbillinae; Haloperidol; Male; | 1994 |
Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzothiazoles; | 1993 |
[Role of the dopaminergic system in experimental models of epilepsy].
Topics: Amygdala; Animals; Benzazepines; Cerebral Cortex; Disease Models, Animal; Dopamine; Dopamine Antagon | 1993 |
The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol.
Topics: Animals; Clozapine; Cricetinae; Disease Models, Animal; Dystonia; Female; Haloperidol; Male; Mesocri | 1993 |
[Epiphyseal interrelations with the striatum in the haloperidol-induced catalepsy model].
Topics: Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Haloperidol; Male; Pineal Gland; Rats; | 1993 |
Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Disease Models, Animal; Dopamine D2 Receptor Antago | 1993 |
Acute blockade of dopamine receptors with haloperidol: a retinal model to study impairments of dopaminergic transmission.
Topics: Animals; Chickens; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electrooculography; Halop | 1993 |
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Hippocamp | 1993 |
Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia.
Topics: Animals; Apomorphine; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Habituati | 1993 |
Role of dopamine D-1 and D-2 antagonists in a model of focal epilepsy induced by electrical stimulation of hippocampus and amygdala in the rabbit.
Topics: Amygdala; Animals; Benzazepines; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor | 1995 |
Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity.
Topics: Animals; Disease Models, Animal; Electromyography; Haloperidol; Joints; Male; Muscle Spasticity; Mus | 1996 |
PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats.
Topics: Animals; Cerebral Infarction; Disease Models, Animal; Haloperidol; Infusions, Intravenous; Ischemic | 1996 |
Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level.
Topics: Animals; Antipsychotic Agents; Atropine; Body Temperature Regulation; Cholinergic Antagonists; Creat | 1996 |
SA4503, a novel cognitive enhancer with sigma1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice.
Topics: Amnesia; Analysis of Variance; Animals; Avoidance Learning; Cognition; Disease Models, Animal; Dizoc | 1997 |
[Zotepin--its value and potentials for further development].
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiepins; Disease Models, Animal; Haloperidol; Huma | 1994 |
Prefrontal cortical and hippocampal modulation of dopamine-mediated effects.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Apomorphine; Disease Models, Animal; Dopamine; Halope | 1998 |
Dopaminergic modulation of lithium/pilocarpine-induced status epilepticus in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Azepines; Benzazepines; Disease | 1997 |
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide S | 1997 |
Kainic acid lesions in adult rats as a model of schizophrenia: changes in auditory information processing.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Auditory Perception; Disease Models, Animal; El | 1998 |
A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dextroamphetamine; Disease Models, Anima | 1998 |
Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Dextroamphetamine; Disease Mod | 1998 |
Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Male; | 1998 |
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 1998 |
Effects of dopaminergic drugs, occlusal disharmonies, and chronic stress on non-functional masticatory activity in the rat, assessed by incisal attrition.
Topics: Analysis of Variance; Animals; Apomorphine; Bruxism; Cocaine; Dental Occlusion, Traumatic; Disease M | 1998 |
Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Indu | 1998 |
Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Electr | 1998 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory | 1998 |
The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Fasciculati | 1999 |
Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; No | 1999 |
Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; GABA Antagonists; GABA-A Receptor Antagonists | 1999 |
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.
Topics: Animals; Antipsychotic Agents; Antisocial Personality Disorder; Behavior, Animal; Calcium Signaling; | 1999 |
Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzazepines; | 1999 |
Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Excitatory A | 1999 |
Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Kava; Male; Plant Ext | 1999 |
Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1999 |
Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats.
Topics: Animals; Biomechanical Phenomena; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Female; G | 2000 |
Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats.
Topics: Amygdala; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Antagonists; Exci | 2000 |
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.
Topics: Animals; Antidepressive Agents; Apomorphine; Carbamazepine; Catalepsy; Disease Models, Animal; Dopam | 2000 |
Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose- | 2000 |
Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dendrites; Disease Models, Animal; Dynorphins; Dysk | 2000 |
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behav | 2000 |
Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.
Topics: Acoustic Stimulation; Adamantane; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Conditioni | 2001 |
Biperiden hydrochlorate ameliorates dystonia of rats produced by microinjection of sigma ligands into the red nucleus.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Biperiden; Disease Models, Animal; Guanidines; Hal | 2000 |
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Benzimidazoles; Bromo | 2001 |
Atypical antipsychotic effects of quetiapine fumarate in animal models.
Topics: Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Disease Models, Anima | 2000 |
Role of the central nervous system in hemopoiesis regulation during experimental neuroses.
Topics: Animals; Brain Chemistry; Central Nervous System; Conflict, Psychological; Cyproheptadine; Disease M | 2001 |
An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Rel | 2001 |
Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43.
Topics: Amphetamine; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine Agents; Dopamine Antagonis | 2001 |
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine; | 2001 |
Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepinones; Central Nervous System Stimulants; Cl | 2001 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bro | 2001 |
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal; | 2001 |
Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG/Rij rats.
Topics: Action Potentials; Animals; Apomorphine; Biological Clocks; Cerebral Cortex; Disease Models, Animal; | 2001 |
The protective effect of hypervolemic hemodilution in experimental heatstroke.
Topics: Analysis of Variance; Animals; Body Temperature; Carbon Dioxide; Corpus Striatum; Disease Models, An | 2001 |
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blepharoptosis; Disease Models, Animal; Dopamine A | 2001 |
Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
Topics: Animals; Anti-Dyskinesia Agents; Central Nervous System Stimulants; Corpus Callosum; Corpus Striatum | 2002 |
Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Anticonvulsants; Antioxidants; Disease Models, Animal; Dyskinesia, | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hipp | 2002 |
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Disease Models, Animal; Dose-Response Rel | 2002 |
[An experimental study of the spectrum of individual psychotropic activity of clozapine (Leponex)].
Topics: Animals; Antipsychotic Agents; Cats; Clozapine; Diazepam; Dibenzazepines; Disease Models, Animal; Ha | 1975 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, | 1976 |
Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Benserazide; Callitrichinae; Disease Models, Animal; Drug Therapy | 1979 |
Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia.
Topics: Animals; Attention; Avoidance Learning; Behavior; Chlorpromazine; Conditioning, Operant; Disease Mod | 1978 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; H | 1977 |
Dyskinesias evoked in monkeys by weekly administration of haloperidol.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Haplorhini; Time Factors | 1978 |
Clinical and experimental studies of phenytoin-induced hyperkinesias.
Topics: Aged; Animals; Apomorphine; Basal Ganglia; Corpus Striatum; Dextroamphetamine; Disease Models, Anima | 1979 |
Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia?
Topics: Animals; Behavior; Dextroamphetamine; Disease Models, Animal; Haloperidol; Humans; Male; Phenethylam | 1977 |
Choline chloride in animal models of tardive dyskinesia.
Topics: Animals; Apomorphine; Choline; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Humans | 1978 |
The effect of lithium on an animal model of tardive dyskinesia.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Guinea Pi | 1977 |
[Pathogenesis of stereotyped behavior].
Topics: Animals; Behavior; Caudate Nucleus; Diazepam; Disease Models, Animal; gamma-Aminobutyric Acid; Halop | 1979 |
Striatal membrane 3H-dopamine binding in an animal model of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Guinea Pigs; H | 1978 |
Effect of centrally acting drugs on experimental torticollis in monkeys.
Topics: Acetates; Alkaloids; Aminooxyacetic Acid; Animals; Brain Stem; Chlorocebus aethiops; Disease Models, | 1976 |
Haloperidol-induced tardive dyskinesia in monkeys.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Haplorhini; Macaca f | 1976 |
Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; | 1975 |
Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; Animals; Antipsych | 1992 |
Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow.
Topics: Animals; Blood Flow Velocity; Bromocriptine; Disease Models, Animal; Domperidone; Dopamine Antagonis | 1992 |
Effects of haloperidol, bromocriptine and amphetamine on the development of Ehrlich ascites carcinoma in mice.
Topics: Amphetamine; Analysis of Variance; Animals; Bromocriptine; Carcinoma, Ehrlich Tumor; Disease Models, | 1992 |
Mapping of cerebral energy metabolism in rats with genetic generalized nonconvulsive epilepsy.
Topics: Animals; Brain; Brain Mapping; Disease Models, Animal; Electroencephalography; Energy Metabolism; Ep | 1992 |
Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; | 1992 |
Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced mov
Topics: Animals; Clozapine; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesi | 1992 |
Inhibition by thyrotropin-releasing hormone of epileptic seizures in spontaneously epileptic rats.
Topics: Animals; Disease Models, Animal; Electrodes; Electroencephalography; Epilepsy; Female; Haloperidol; | 1991 |
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Topics: Animals; Antipsychotic Agents; Arousal; Benzamides; Cebus; Disease Models, Animal; Dyskinesia, Drug- | 1990 |
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Disease M | 1990 |
Differential modulation of mouse brain biogenic amines by haloperidol and pimozide: implications in Tourette's syndrome.
Topics: Animals; Biogenic Amines; Brain; Disease Models, Animal; Haloperidol; Humans; Male; Mice; Mice, Inbr | 1990 |
Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Topics: Animals; Antipsychotic Agents; Atropine; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperid | 1990 |
The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.
Topics: Animals; Appetitive Behavior; Arousal; Association Learning; Attention; Brain; Conditioning, Classic | 1991 |
Conditioned drug effects of pimozide, haloperidol and chlorpromazine on methamphetamine-induced behavior.
Topics: Animals; Arousal; Chlorpromazine; Conditioning, Classical; Disease Models, Animal; Dose-Response Rel | 1990 |
Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat.
Topics: Animals; Catheterization; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; | 1990 |
Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome?
Topics: Animals; Brain; Bromocriptine; Disease Models, Animal; Haloperidol; Halothane; Hyperthermia, Induced | 1990 |
Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
Topics: Animals; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-In | 1990 |
Is experimental catalepsy properly measured?
Topics: Adrenal Glands; Animals; Apomorphine; Catalepsy; Disease Models, Animal; Drug Interactions; Haloperi | 1990 |
A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat.
Topics: Animals; Atropine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 1990 |
Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Body Weight; Clozapine; Dibenzazepines; Disease Models, Animal; Drinking; | 1990 |
Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
Topics: Animals; Autoradiography; Behavior, Animal; Benzazepines; Brain; Disease Models, Animal; Dyskinesia, | 1989 |
Ketamine-induced tongue protrusions in rats.
Topics: Animals; Deglutition; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Hypoglo | 1989 |
[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Topics: Animals; Catalepsy; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; gamma-Aminobut | 1989 |
The pathophysiology of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disea | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluatio | 1985 |
Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Topics: Animals; Antipsychotic Agents; Benztropine; Cebus; Death, Sudden; Disease Models, Animal; Drug Thera | 1985 |
Haloperidol-induced emotional defecation: a possible model for neuroleptic anxiety syndrome.
Topics: Animals; Antipsychotic Agents; Anxiety; Corpus Striatum; Defecation; Digestive System; Disease Model | 1987 |
[The influences of neurotransmitters on the traumatic unconsciousness, immediate convulsion and mortality in the experimental mice model].
Topics: Animals; Atropine; Craniocerebral Trauma; Disease Models, Animal; Haloperidol; Male; Methamphetamine | 1987 |
Enhancement by haloperidol of the locomotor response induced by naloxone in morphine-treated guinea pigs.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Guinea Pigs; Haloperidol; | 1989 |
The effects of carbamazepine on two animal models of depression.
Topics: Animals; Carbamazepine; Depressive Disorder; Disease Models, Animal; Haloperidol; Imipramine; Male; | 1987 |
L-5-HTP-induced myoclonic jumping behavior in guinea pigs: an update.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Bromocriptine; Clonazepam; Disease Models, Animal; Guinea | 1986 |
Animal models for schizophrenia: the hippocampally lesioned animal.
Topics: Animals; Attention; Disease Models, Animal; Dopamine Antagonists; Galvanic Skin Response; Haloperido | 1987 |
Head displacement and bracing in haloperidol-treated rats compared to rats with lateral hypothalamic damage.
Topics: Animals; Brain Diseases; Catalepsy; Disease Models, Animal; Haloperidol; Hydroxydopamines; Hypothala | 1985 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Fronta | 1974 |
Rigidity and tremor induced in feline muscles deprived of their fusiomtor control.
Topics: Achilles Tendon; Animals; Animals, Newborn; Cats; Disease Models, Animal; Electromyography; Haloperi | 1974 |
Studies in experimental spinal cord trauma. 2. Comparison of treatment with steroids, low molecular weight dextran, and catecholamine blockade.
Topics: Animals; Dextrans; Disease Models, Animal; Dogs; Edema; Glucocorticoids; Haloperidol; Hypoxia; Methy | 1974 |
A Stretchable and Transparent Electrode Based on PEGylated Silk Fibroin for In Vivo Dual-Modal Neural-Vascular Activity Probing.
Topics: Animals; Brain-Computer Interfaces; Disease Models, Animal; Elastic Modulus; Electric Conductivity; | 2021 |
Evaluation of Inflammatory Response to Endodontic Sealers in a Bone Defect Animal Model.
Topics: Aluminum Compounds; Animals; Biocompatible Materials; Calcium Compounds; Disease Models, Animal; Dru | 2016 |
Cholangiocytes of cirrhotic rats are more tolerant to ischemia than normal rats: a role for abnormal hepatic arteriovenous communications?
Topics: Animals; Apoptosis; Arteriovenous Fistula; Bile Ducts; Blood Circulation; Disease Models, Animal; Ep | 2011 |
A new primate model of focal stroke: endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset.
Topics: Animals; Behavior, Animal; Brain; Callithrix; Conditioning, Operant; Disease Models, Animal; Dose-Re | 2004 |
The effect of intracanal anti-inflammatory medicaments on external root resorption of replanted dog teeth after extended extra-oral dry time.
Topics: Animals; Anti-Inflammatory Agents; Demeclocycline; Dental Alloys; Desiccation; Disease Models, Anima | 2008 |
Heparinization on pericardial substitutes can reduce adhesion and epicardial inflammation in the dog.
Topics: Animals; Anticoagulants; Biocompatible Materials; Disease Models, Animal; Dogs; Epoxy Resins; Follow | 1998 |
Allergenicity of epoxy resins in the guinea pig.
Topics: Allergens; Animals; Dermatitis, Contact; Disease Models, Animal; Epichlorohydrin; Epoxy Resins; Fema | 1977 |
Picroside III, an Active Ingredient of Picrorhiza scrophulariiflora, Ameliorates Experimental Colitis by Protecting Intestinal Barrier Integrity.
Topics: AMP-Activated Protein Kinases; Animals; Caco-2 Cells; Claudin-2; Claudin-3; Colitis; Disease Models, | 2023 |